Sequence Search

Roy Teller 10/015,055

```
=> d his

     (FILE 'REGISTRY' ENTERED AT 11:37:09 ON 26 FEB 2004)
                DEL HIS Y
L1         141495 S KPV/SQSP
L2           1163 S KPV^/SQSP

     FILE 'CAPLUS' ENTERED AT 11:37:58 ON 26 FEB 2004
L3           1250 S L2
L4          15075 S SINUS? OR RESPIRATOR? (L) (DISEASE? OR DISORDER?)
L5              5 S L3 AND L4
L6            101 S L2 AND 63/SX,SC
L7          47335 S PROTEIN MOTIFS
L8             41 S L3 AND L7
L9          18958 S C(L)TERMIN?
L10             2 S L9 AND L8
L11             2 S KPV (L) L9

     FILE 'REGISTRY' ENTERED AT 11:43:07 ON 26 FEB 2004

     FILE 'CAPLUS' ENTERED AT 11:43:29 ON 26 FEB 2004
L12             7 S L5 OR L10 OR L11
```

=> fil refg
'REFG' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'CAPLUS'

=> fil reg
FILE 'REGISTRY' ENTERED AT 11:44:26 ON 26 FEB 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 24 FEB 2004 HIGHEST RN 654050-72-3
DICTIONARY FILE UPDATES: 24 FEB 2004 HIGHEST RN 654050-72-3

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d que l1;d que l2
L1 141495 SEA FILE=REGISTRY ABB=ON PLU=ON KPV/SQSP

L2 1163 SEA FILE=REGISTRY ABB=ON PLU=ON KPV^/SQSP

sequence search KPV at C terminal

=> fil caplus
FILE 'CAPLUS' ENTERED AT 11:44:34 ON 26 FEB 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 26 Feb 2004 VOL 140 ISS 9
FILE LAST UPDATED: 25 Feb 2004 (20040225/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

```
=> d que nos l12
L2          1163 SEA FILE=REGISTRY ABB=ON  PLU=ON  KPV^/SQSP
L3          1250 SEA FILE=CAPLUS ABB=ON  PLU=ON  L2
L4         15075 SEA FILE=CAPLUS ABB=ON  PLU=ON  SINUS?/OBI OR RESPIRATOR?/OBI
                 (L) (DISEASE?/OBI OR DISORDER?/OBI)
L5             5 SEA FILE=CAPLUS ABB=ON  PLU=ON  L3 AND L4
L7         47335 SEA FILE=CAPLUS ABB=ON  PLU=ON  PROTEIN MOTIFS/OBI
L8            41 SEA FILE=CAPLUS ABB=ON  PLU=ON  L3 AND L7
L9         18958 SEA FILE=CAPLUS ABB=ON  PLU=ON  C/OBI(L)TERMIN?/OBI
L10            2 SEA FILE=CAPLUS ABB=ON  PLU=ON  L9 AND L8
L11            2 SEA FILE=CAPLUS ABB=ON  PLU=ON  KPV/OBI (L) L9
L12            7 SEA FILE=CAPLUS ABB=ON  PLU=ON  L5 OR L10 OR L11


=> d .ca l12 1-7

L12  ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         2003:719958  CAPLUS
DOCUMENT NUMBER:          139:208598
TITLE:                    Comparative analysis of the genome sequences of
                          Bordetella pertussis, Bordetella parapertussis and
                          Bordetella bronchiseptica
AUTHOR(S):                Parkhill, Julian; Sebaihia, Mohammed; Preston, Andrew;
                          Murphy, Lee D.; Thomson, Nicholas; Harris, David E.;
                          Holden, Matthew T. G.; Churcher, Carol M.; Bentley,
                          Stephen D.; Mungall, Karen L.; Cerdeno-Tarraga, Ana
                          M.; Temple, Louise; James, Keith; Harris, Barbara;
                          Quail, Michael A.; Achtman, Mark; Atkin, Rebecca;
                          Baker, Steven; Basham, David; Bason, Nathalie;
                          Cherevach, Inna; Chillingworth, Tracey; Collins,
                          Matthew; Cronin, Anne; Davis, Paul; Doggett, Jonathan;
                          Feltwell, Theresa; Goble, Arlette; Hamlin, Nancy;
                          Hauser, Heidi; Holroyd, Simon; Jagels, Kay; Leather,
                          Sampsa; Moule, Sharon; Norberczak, Halina; O'Neil,
                          Susan; Ormond, Doug; Price, Claire; Rabbinowitsch,
                          Ester; Rutter, Simon; Sanders, Mandy; Saunders, David;
                          Seeger, Katherine; Sharp, Sarah; Simmonds, Mark;
                          Skelton, Jason; Squares, Robert; Squares, Steven;
                          Stevens, Kim; Unwin, Louise; Whitehead, Sally;
                          Barrell, Bart G.; Maskell, Duncan J.
CORPORATE SOURCE:         Wellcome Trust Genome Campus, The Sanger Institute,
                          Hinxton, Cambridge, CB10 1SA, UK
SOURCE:                   Nature Genetics (2003), 35(1), 32-40
                          CODEN: NGENEC; ISSN: 1061-4036
PUBLISHER:                Nature Publishing Group
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
AB   Bordetella pertussis, Bordetella parapertussis and Bordetella
     bronchiseptica are closely related Gram-neg. β-proteobacteria that
     colonize the respiratory tracts of mammals.  B. pertussis is a strict
     human pathogen of recent evolutionary origin and is the primary etiol.
     agent of whooping cough.  B. parapertussis can also cause whooping cough,
     and B. bronchiseptica causes chronic respiratory infections in a wide
     range of animals.  The genomes of B. bronchiseptica RB50 (5,338,400 bp;
     5007 predicted genes), B. parapertussis 12822 (4,773,551 bp; 4404 genes),
     and B. pertussis Tohama I (4,086,186 bp; 3816 genes) were sequenced.
     Anal. indicates that B. parapertussis and B. pertussis are independent
     derivs. of B. bronchiseptica-like ancestors.  During the evolution of
```

these two host-restricted species there was large-scale gene loss and inactivation; host adaptation seems to be a consequence of loss, not gain, of function, and differences in virulence may be related to loss of regulatory or control functions. [This abstract record is one of three records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 6, 10

IT **Respiratory** tract, **disease**
(infection; comparative anal. of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica)

IT

565135-97-9	565135-98-0	565135-99-1	565136-00-7	565136-01-8
565136-02-9	565136-03-0	565136-04-1	565136-05-2	565136-06-3
565136-07-4	565136-08-5	565136-09-6	565136-10-9	565136-11-0
565136-12-1	565136-13-2	565136-14-3	565136-15-4	565136-16-5
565136-17-6	565136-18-7	565136-19-8	565136-20-1	565136-21-2
565136-22-3	565136-23-4	565136-24-5	565136-25-6	565136-26-7
565136-27-8	565136-28-9	565136-29-0	565136-30-3	565136-31-4
565136-32-5	565136-33-6	565136-34-7	565136-35-8	565136-36-9
565136-37-0	565136-38-1	565136-39-2	565136-40-5	565136-41-6
565136-42-7	565136-43-8	565136-44-9	565136-45-0	565136-46-1
565136-47-2	565136-48-3	565136-49-4	565136-50-7	565136-51-8
565136-52-9	565136-53-0	565136-54-1	565136-55-2	565136-56-3
565136-57-4	565136-58-5	565136-59-6	565136-60-9	565136-61-0
565136-62-1	565136-63-2	565136-64-3	565136-65-4	565136-66-5
565136-67-6	565136-68-7	565136-69-8	565136-70-1	565136-71-2
565136-72-3	565136-73-4	565136-74-5	565136-75-6	565136-76-7
565136-77-8	565136-78-9	565136-79-0	**565136-80-3**	
565136-81-4	565136-82-5	565136-83-6	565136-84-7	565136-85-8
565136-86-9	565136-87-0	565136-88-1	565136-89-2	565136-90-5
565136-91-6	565136-92-7	565136-93-8	565136-94-9	565136-95-0
565136-96-1	565136-97-2	565136-98-3	565136-99-4	565137-00-0
565137-01-1	565137-02-2	565137-03-3	565137-04-4	565137-05-5
565137-06-6	565137-07-7	565137-08-8	565137-09-9	565137-10-2
565137-11-3	565137-12-4	565137-13-5	565137-14-6, GenBank CAE30950	
565137-15-7	565137-16-8	565137-17-9	565137-18-0	565137-19-1
565137-20-4	565137-21-5	565137-22-6	565137-23-7	565137-24-8
565137-25-9	565137-26-0	565137-27-1	565137-28-2	565137-29-3
565137-30-6	565137-31-7	565137-32-8	565137-33-9	565137-34-0
565137-35-1	565137-36-2	565137-37-3	565137-38-4	565137-39-5
565137-40-8	565137-41-9	565137-42-0	565137-43-1	565137-44-2
565137-45-3	565137-46-4	565137-47-5	565137-48-6	565137-49-7
565137-50-0	565137-51-1	565137-52-2	565137-53-3	565137-54-4
565137-55-5	565137-56-6	565137-57-7	565137-58-8	565137-59-9
565137-60-2	565137-61-3	565137-62-4	565137-63-5	565137-64-6
565137-65-7	565137-66-8	565137-67-9	565137-68-0	565137-69-1
565137-70-4	565137-71-5	565137-72-6	565137-73-7	565137-74-8
565137-75-9	565137-76-0	565137-77-1	565137-78-2	565137-79-3
565137-80-6	565137-81-7	565137-82-8	565137-83-9	565137-84-0
565137-85-1	565137-86-2	565137-87-3	565137-88-4	565137-89-5
565137-90-8	565137-91-9	565137-92-0	565137-93-1	565137-94-2
565137-95-3	565137-96-4	565137-97-5	565137-98-6	565137-99-7
565138-00-3	565138-01-4	565138-02-5	565138-03-6	565138-04-7
565138-05-8	565138-06-9	565138-07-0	565138-08-1	565138-09-2
565138-10-5	565138-11-6	565138-12-7	565138-13-8	565138-14-9
565138-15-0	565138-16-1	565138-17-2	565138-18-3	565138-19-4
565138-20-7	565138-21-8	565138-22-9	565138-23-0	565138-24-1
565138-25-2	565138-26-3	565138-27-4	565138-28-5	565138-29-6
565138-30-9	565138-31-0	565138-32-1	565138-33-2	565138-34-3

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

(Biological study)
(amino acid sequence; comparative anal. of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica)

IT 566130-35-6 566130-36-7 566130-37-8 566130-38-9 566130-39-0
566130-40-3 566130-41-4 566130-42-5 566130-43-6 566130-44-7
566130-45-8 566130-46-9 566130-47-0 566130-48-1 566130-49-2
566130-50-5 566130-51-6 566130-52-7 566130-53-8 566130-54-9
566130-55-0 566130-56-1 566130-57-2 566130-58-3 566130-59-4
566130-60-7 566130-61-8 566130-62-9 566130-63-0 566130-64-1
566130-65-2 566130-66-3 566130-67-4 566130-68-5 566130-69-6
566130-70-9 566130-71-0 566130-72-1 566130-73-2 566130-74-3
566130-75-4 566130-76-5 566130-77-6 566130-78-7 566130-79-8
566130-80-1 566130-81-2 566130-82-3 566130-83-4 566130-84-5
566130-85-6 566130-86-7 566130-87-8 566130-88-9 566130-89-0
566130-90-3 566130-91-4 566130-92-5 566130-93-6 566130-94-7
566130-95-8, GenBank CAE34859 566130-96-9 566130-97-0 566130-98-1
566130-99-2 566131-00-8 566131-01-9 566131-02-0 566131-03-1
566131-04-2 566131-05-3 566131-06-4 566131-07-5 566131-08-6
566131-09-7 566131-10-0 566131-11-1 566131-12-2 566131-13-3
566131-14-4 566131-15-5 566131-16-6 566131-17-7 566131-18-8
566131-19-9 566131-20-2 566131-21-3 566131-22-4 566131-23-5
566131-24-6 566131-25-7 566131-26-8 566131-27-9 566131-28-0
566131-29-1 566131-30-4 566131-31-5 566131-32-6 566131-33-7
566131-34-8 566131-35-9 566131-36-0 566131-37-1 566131-38-2
566131-39-3 566131-40-6 566131-41-7 566131-42-8 566131-43-9
566131-44-0 566131-45-1 566131-46-2 566131-47-3 566131-48-4
566131-49-5 566131-50-8 566131-51-9 566131-52-0 566131-53-1
566131-54-2 566131-55-3 566131-56-4 566131-57-5 566131-58-6
566131-59-7 566131-60-0 566131-61-1 566131-62-2 566131-63-3
566131-64-4 566131-65-5 566131-66-6 566131-67-7 566131-68-8
566131-69-9 566131-70-2 566131-71-3 566131-72-4 566131-74-6
566131-75-7 566131-76-8 566131-77-9 566131-78-0 566131-79-1
566131-80-4 566131-81-5 566131-82-6 566131-83-7 566131-84-8
566131-85-9 566131-86-0 566131-87-1 566131-88-2 566131-89-3
566131-90-6 566131-91-7 566131-92-8 566131-93-9 566131-94-0
566131-95-1 566131-96-2 566131-97-3 566131-98-4 566131-99-5
566132-00-1 566132-01-2 566132-02-3 566132-03-4 566132-04-5
566132-05-6 566132-06-7 566132-07-8 566132-08-9 566132-09-0
566132-10-3 566132-11-4 566132-12-5 566132-13-6 566132-14-7
566132-15-8 566132-16-9 566132-17-0 566132-18-1 566132-19-2
566132-20-5 566132-21-6 566132-22-7 566132-23-8 566132-24-9
566132-25-0 566132-26-1 566132-27-2 566132-28-3 566132-29-4
566132-30-7 566132-31-8 566132-32-9 566132-33-0 566132-34-1
566132-35-2 566132-36-3 566132-37-4 566132-38-5 566132-39-6
566132-40-9 566132-41-0 566132-42-1 566132-43-2 566132-44-3
566132-45-4 566132-46-5 **566132-47-6** 566132-48-7
566132-49-8 566132-50-1 566132-51-2 566132-52-3 566132-53-4
566132-54-5 566132-55-6 566132-56-7 566132-57-8 566132-58-9
566132-59-0 566132-60-3 566132-61-4 566132-62-5 566132-63-6
566132-64-7 566132-65-8 566132-66-9 566132-67-0 566132-68-1
566132-69-2 566132-70-5 566132-71-6 566132-72-7 566132-73-8
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; comparative anal. of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica)

L12 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:719957 CAPLUS

DOCUMENT NUMBER: 139:208597
TITLE: Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica
AUTHOR(S): Parkhill, Julian; Sebaihia, Mohammed; Preston, Andrew; Murphy, Lee D.; Thomson, Nicholas; Harris, David E.; Holden, Matthew T. G.; Churcher, Carol M.; Bentley, Stephen D.; Mungall, Karen L.; Cerdeno-Tarraga, Ana M.; Temple, Louise; James, Keith; Harris, Barbara; Quail, Michael A.; Achtman, Mark; Atkin, Rebecca; Baker, Steven; Basham, David; Bason, Nathalie; Cherevach, Inna; Chillingworth, Tracey; Collins, Matthew; Cronin, Anne; Davis, Paul; Doggett, Jonathan; Feltwell, Theresa; Goble, Arlette; Hamlin, Nancy; Hauser, Heidi; Holroyd, Simon; Jagels, Kay; Leather, Sampsa; Moule, Sharon; Norberczak, Halina; O'Neil, Susan; Ormond, Doug; Price, Claire; Rabbinowitsch, Ester; Rutter, Simon; Sanders, Mandy; Saunders, David; Seeger, Katherine; Sharp, Sarah; Simmonds, Mark; Skelton, Jason; Squares, Robert; Squares, Steven; Stevens, Kim; Unwin, Louise; Whitehead, Sally; Barrell, Bart G.; Maskell, Duncan J.
CORPORATE SOURCE: Wellcome Trust Genome Campus, The Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK
SOURCE: Nature Genetics (2003), 35(1), 32-40
CODEN: NGENEC; ISSN: 1061-4036
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica are closely related Gram-neg. β-proteobacteria that colonize the respiratory tracts of mammals. B. pertussis is a strict human pathogen of recent evolutionary origin and is the primary etiol. agent of whooping cough. B. parapertussis can also cause whooping cough, and B. bronchiseptica causes chronic respiratory infections in a wide range of animals. The genomes of B. bronchiseptica RB50 (5,338,400 bp; 5007 predicted genes), B. parapertussis 12822 (4,773,551 bp; 4404 genes), and B. pertussis Tohama I (4,086,186 bp; 3816 genes) were sequenced. Anal. indicates that B. parapertussis and B. pertussis are independent derivs. of B. bronchiseptica-like ancestors. During the evolution of these two host-restricted species there was large-scale gene loss and inactivation; host adaptation seems to be a consequence of loss, not gain, of function, and differences in virulence may be related to loss of regulatory or control functions. [This abstract record is one of three records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].
CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 6, 10
IT **Respiratory** tract, **disease**
(infection; comparative anal. of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica)
IT 565117-15-9 565117-16-0 565117-17-1 565117-18-2 565117-19-3
565117-20-6 565117-21-7 565117-22-8 565117-23-9 565117-24-0
565117-25-1 565117-26-2 565117-27-3 565117-28-4 565117-29-5
565117-30-8 565117-31-9 565117-32-0 565117-33-1 565117-34-2
565117-35-3 565117-36-4 565117-37-5 565117-38-6 565117-39-7
565117-40-0 565117-41-1 565117-42-2 565117-43-3 565117-44-4
565117-45-5 565117-46-6 565117-47-7 565117-48-8 565117-49-9
565117-50-2 565117-51-3 565117-52-4 565117-53-5 565117-54-6
565117-55-7 565117-56-8 565117-57-9 565117-58-0 565117-59-1

565117-60-4 565117-61-5 565117-62-6 565117-63-7 565117-64-8
565117-65-9 565117-66-0 565117-67-1 565117-68-2 565117-69-3
565117-70-6 565117-71-7 565117-72-8 565117-73-9 565117-74-0
565117-75-1 565117-76-2 565117-77-3 565117-78-4 565117-79-5
565117-80-8 565117-81-9 565117-82-0 565117-83-1 565117-84-2
565117-85-3 565117-86-4 565117-87-5 565117-88-6 565117-89-7
565117-90-0 565117-91-1 565117-93-3 565117-94-4 565117-95-5
565117-96-6 565117-97-7 565117-98-8 565117-99-9 565118-00-5
565118-01-6 565118-02-7 565118-03-8 565118-04-9 565118-05-0
565118-06-1 565118-07-2 565118-08-3 565118-09-4 565118-10-7
565118-11-8 565118-12-9 565118-13-0 565118-14-1 565118-15-2
565118-16-3 565118-17-4 565118-18-5 565118-19-6 565118-20-9
565118-21-0 565118-22-1 565118-23-2 565118-24-3 565118-25-4
565118-26-5 565118-27-6 565118-28-7 565118-29-8 565118-30-1
565118-31-2 565118-32-3 565118-33-4 565118-34-5 565118-35-6
565118-36-7 565118-37-8 565118-38-9 565118-39-0 565118-40-3
565118-41-4 565118-42-5 565118-43-6 565118-44-7 565118-45-8
565118-46-9 565118-47-0 565118-48-1 565118-49-2 565118-50-5
565118-51-6 565118-52-7 565118-53-8 565118-54-9 565118-55-0
565118-56-1 565118-57-2 565118-58-3 565118-59-4 565118-60-7
565118-61-8 565118-62-9 565118-63-0 565118-64-1 565118-65-2
565118-66-3 565118-67-4 565118-68-5 565118-69-6 565118-70-9
565118-71-0 565118-72-1 565118-73-2 565118-74-3 565118-75-4
565118-76-5 565118-77-6 565118-78-7 **565118-79-8**
565118-80-1 565118-81-2 565118-82-3 565118-83-4 565118-84-5
565118-85-6 565118-86-7 565118-87-8 565118-88-9 565118-89-0
565118-90-3 565118-91-4 565118-92-5 565118-93-6 565118-94-7
565118-95-8 565118-96-9 565118-97-0 565118-98-1 565118-99-2
565119-00-8 565119-01-9 565119-02-0 565119-03-1 565119-04-2
565119-05-3 565119-06-4 565119-07-5 565119-08-6 565119-09-7
565119-10-0 565119-11-1 565119-12-2 565119-13-3, GenBank CAE36034
565119-14-4 565119-15-5 565119-16-6 565119-17-7 565119-18-8
565119-19-9 565119-20-2 565119-21-3 565119-22-4 565119-23-5
565119-24-6 565119-25-7 565119-26-8 565119-27-9 565119-28-0
565119-29-1 565119-30-4 565119-31-5 565119-32-6 565119-33-7
565119-34-8 565119-35-9 565119-36-0 565119-37-1 565119-38-2
565119-39-3 565119-40-6 565119-41-7 565119-42-8 565119-43-9
565119-44-0 565119-45-1 565119-46-2 565119-47-3 565119-48-4
565119-49-5 565119-50-8 565119-51-9 565119-52-0 565119-53-1
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; comparative anal. of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica)

IT 566101-65-3 566101-66-4 566101-67-5 566101-68-6 566101-69-7
566101-70-0 566101-71-1 566101-72-2 566101-73-3 566101-74-4
566101-75-5 566101-76-6 566101-77-7 566101-78-8 566101-79-9
566101-80-2 566101-81-3 566101-82-4 566101-83-5 566101-84-6
566101-85-7 566101-86-8 566101-87-9 566101-88-0 566101-89-1
566101-90-4 566101-91-5 566101-92-6 566101-93-7 566101-94-8
566101-95-9 566101-96-0 566101-97-1 566101-98-2 566101-99-3
566102-00-9 566102-01-0 566102-02-1 566102-03-2 566102-04-3
566102-05-4 566102-06-5 566102-07-6 566102-08-7 566102-09-8
566102-10-1 566102-11-2 566102-12-3 566102-13-4 566102-14-5
566102-15-6 566102-16-7 566102-17-8 566102-18-9 566102-19-0
566102-20-3 566102-21-4 566102-22-5 566102-23-6 566102-24-7
566102-25-8 566102-26-9 566102-27-0 566102-28-1 566102-29-2
566102-30-5 566102-31-6 566102-32-7 566102-33-8 566102-34-9
566102-35-0 566102-36-1 566102-37-2 566102-38-3 566102-39-4
566102-40-7 566102-41-8 566102-42-9 566102-43-0 566102-44-1

566102-45-2 566102-46-3 566102-47-4 566102-48-5 566102-49-6
566102-50-9 566102-51-0 566102-52-1 566102-53-2 566102-54-3
566102-55-4 566102-56-5 566102-57-6 566102-58-7 566102-59-8
566102-60-1 566102-61-2 566102-62-3 566102-63-4 566102-64-5
566102-65-6 566102-66-7 566102-67-8 566102-68-9 566102-69-0
566102-70-3 566102-71-4 566102-72-5 566102-73-6 566102-74-7
566102-75-8 566102-76-9 566102-77-0 566102-78-1 566102-79-2
566102-80-5 566102-81-6 566102-82-7 566102-83-8 566102-84-9
566102-85-0 566102-86-1 566102-87-2 566102-88-3 566102-89-4
566102-90-7 566102-91-8 566102-92-9 566102-93-0 566102-94-1
566102-95-2 566102-96-3 566102-97-4 566102-98-5 566102-99-6
566103-00-2 **566103-01-3** 566103-02-4 566103-03-5
566103-04-6 566103-05-7 566103-06-8 566103-08-0 566103-09-1
566103-10-4 566103-11-5 566103-12-6 566103-13-7 566103-14-8
566103-15-9 566103-16-0 566103-17-1 566103-18-2 566103-19-3
566103-20-6 566103-21-7 566103-22-8 566103-23-9 566103-24-0
566103-25-1 566103-26-2 566103-27-3 566103-28-4 566103-29-5
566103-30-8 566103-31-9 566103-32-0 566103-33-1 566103-34-2
566103-35-3 566103-36-4 566103-37-5 566103-38-6 566103-39-7
566103-40-0 566103-41-1 566103-42-2 566103-43-3 566103-44-4
566103-45-5 566103-46-6 566103-47-7 566103-48-8 566103-49-9
566103-50-2 566103-51-3 566103-52-4 566103-53-5 566103-54-6
566103-55-7 566103-56-8 566103-57-9 566103-58-0 566103-59-1
566103-60-4 566103-61-5, GenBank CAE39520 566103-62-6 566103-63-7
566103-64-8 566103-65-9 566103-66-0 566103-67-1 566103-68-2
566103-69-3 566103-70-6 566103-71-7 566103-72-8 566103-73-9
566103-74-0 566103-75-1 566103-76-2 566103-77-3 566103-78-4
566103-79-5 566103-80-8 566103-81-9 566103-82-0 566103-83-1
566103-84-2 566103-85-3 566103-86-4 566103-87-5 566103-88-6
566103-89-7 566103-90-0 566103-91-1 566103-92-2 566103-93-3
566103-94-4 566103-95-5 566103-96-6 566103-97-7 566103-98-8
566103-99-9 566104-00-5 566104-01-6 566104-02-7 566104-03-8
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; comparative anal. of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica)

L12 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:673597 CAPLUS
DOCUMENT NUMBER: 139:208590
TITLE: Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica
AUTHOR(S): Parkhill, Julian; Sebaihia, Mohammed; Preston, Andrew; Murphy, Lee D.; Thomson, Nicholas; Harris, David E.; Holden, Matthew T. G.; Churcher, Carol M.; Bentley, Stephen D.; Mungall, Karen L.; Cerdeno-Tarraga, Ana M.; Temple, Louise; James, Keith; Harris, Barbara; Quail, Michael A.; Achtman, Mark; Atkin, Rebecca; Baker, Steven; Basham, David; Bason, Nathalie; Cherevach, Inna; Chillingworth, Tracey; Collins, Matthew; Cronin, Anne; Davis, Paul; Doggett, Jonathan; Feltwell, Theresa; Goble, Arlette; Hamlin, Nancy; Hauser, Heidi; Holroyd, Simon; Jagels, Kay; Leather, Sampsa; Moule, Sharon; Norberczak, Halina; O'Neil, Susan; Ormond, Doug; Price, Claire; Rabbinowitsch, Ester; Rutter, Simon; Sanders, Mandy; Saunders, David; Seeger, Katherine; Sharp, Sarah; Simmonds, Mark; Skelton, Jason; Squares, Robert; Squares, Steven;

Stevens, Kim; Unwin, Louise; Whitehead, Sally; Barrell, Bart G.; Maskell, Duncan J.
CORPORATE SOURCE: Wellcome Trust Genome Campus, The Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK
SOURCE: Nature Genetics (2003), 35(1), 32-40
CODEN: NGENEC; ISSN: 1061-4036
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica are closely related Gram-neg. β-proteobacteria that colonize the respiratory tracts of mammals. B. pertussis is a strict human pathogen of recent evolutionary origin and is the primary etiol. agent of whooping cough. B. parapertussis can also cause whooping cough, and B. bronchiseptica causes chronic respiratory infections in a wide range of animals. The genomes of B. bronchiseptica RB50 (5,338,400 bp; 5007 predicted genes), B. parapertussis 12822 (4,773,551 bp; 4404 genes), and B. pertussis Tohama I (4,086,186 bp; 3816 genes) were sequenced. Anal. indicates that B. parapertussis and B. pertussis are independent derivs. of B. bronchiseptica-like ancestors. During the evolution of these two host-restricted species there was large-scale gene loss and inactivation; host adaptation seems to be a consequence of loss, not gain, of function, and differences in virulence may be related to loss of regulatory or control functions. [This abstract record is one of three records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].
CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 6, 10
IT **Respiratory** tract, **disease**
(infection; comparative anal. of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica)

IT

566064-39-9	566064-40-2	566064-41-3	566064-42-4	566064-43-5
566064-44-6	566064-45-7	566064-46-8	566064-47-9	566064-48-0
566064-49-1	566064-50-4	566064-51-5	566064-52-6	566064-53-7
566064-54-8	566064-55-9	566064-56-0	566064-57-1	566064-58-2
566064-59-3	566064-60-6	566064-61-7	566064-62-8	566064-63-9
566064-64-0	566064-65-1	566064-66-2	566064-67-3	566064-68-4
566064-69-5	566064-70-8	566064-71-9	566064-72-0	566064-73-1
566064-74-2	566064-75-3	566064-76-4	566064-77-5	566064-78-6
566064-79-7	566064-80-0	566064-81-1	566064-82-2	566064-83-3
566064-84-4	566064-85-5	566064-86-6	566064-87-7	566064-88-8
566064-89-9	566064-90-2	566064-91-3	566064-92-4	566064-93-5
566064-94-6	566064-95-7	566064-96-8	566064-97-9	566064-98-0
566064-99-1	566065-00-7	566065-01-8	566065-02-9	566065-03-0
566065-04-1	566065-05-2	566065-06-3	566065-07-4	566065-08-5
566065-09-6	566065-10-9	566065-11-0	566065-12-1	566065-13-2
566065-14-3	566065-15-4	566065-16-5	566065-17-6	566065-18-7
566065-19-8	566065-20-1	566065-21-2	566065-22-3	566065-23-4
566065-24-5	566065-25-6	566065-26-7	566065-27-8	566065-28-9
566065-29-0	566065-30-3	566065-31-4	566065-32-5	566065-33-6
566065-34-7	566065-35-8	566065-36-9	566065-37-0	566065-38-1
566065-39-2	566065-40-5	566065-41-6	566065-42-7	566065-43-8
566065-44-9	566065-45-0	566065-46-1	566065-47-2	566065-48-3
566065-49-4	566065-50-7	566065-51-8	566065-52-9	566065-53-0
566065-54-1	566065-55-2	566065-56-3	566065-57-4	566065-58-5
566065-59-6	566065-60-9	566065-61-0	566065-62-1	566065-63-2
566065-64-3	566065-65-4	566065-66-5	566065-67-6	566065-68-7
566065-69-8	566065-70-1	566065-71-2	566065-72-3	566065-73-4
566065-74-5	566065-75-6	566065-76-7	566065-77-8	566065-78-9
566065-79-0	566065-80-3	566065-81-4	566065-82-5	566065-83-6

566065-84-7 566065-85-8 566065-86-9 566065-87-0 566065-88-1
566065-89-2 566065-90-5 566065-91-6 566065-92-7 566065-93-8
566065-94-9 566065-95-0 566065-96-1 566065-97-2 566065-98-3
566065-99-4 566066-00-0 566066-01-1 566066-02-2 566066-03-3
566066-04-4 566066-05-5 566066-06-6 566066-07-7 **566066-08-8**
566066-09-9 566066-10-2 566066-11-3 566066-12-4 566066-13-5
566066-14-6 566066-15-7 566066-16-8 566066-17-9 566066-18-0
566066-19-1 566066-20-4 566066-21-5 566066-22-6 566066-23-7
566066-24-8 566066-25-9 566066-26-0 566066-27-1 566066-28-2
566066-29-3 566066-30-6 566066-31-7 566066-32-8 566066-33-9
566066-34-0 566066-35-1 566066-36-2 566066-37-3 566066-38-4
566066-39-5 566066-40-8 566066-41-9 566066-42-0 566066-43-1
566066-44-2 566066-45-3 566066-46-4 566066-47-5, GenBank CAE40641
566066-48-6 566066-49-7 566066-50-0 566066-51-1 566066-52-2
566066-53-3 566066-54-4, GenBank CAE40650 566066-55-5 566066-56-6
566066-57-7 566066-58-8 566066-59-9 566066-60-2 566066-61-3
566066-62-4 566066-63-5 566066-64-6 566066-65-7 566066-66-8
566066-67-9 566066-68-0 566066-69-1 566066-70-4 566066-71-5
566066-72-6 566066-73-7 566066-74-8 566066-75-9 566066-76-0
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; comparative anal. of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica)

IT 566066-77-1 566066-78-2 566066-79-3 566066-80-6 566066-81-7
566066-82-8 566066-83-9 566066-84-0 566066-85-1 566066-86-2
566066-87-3 566066-88-4 566066-89-5 566066-90-8 566066-91-9
566066-92-0 566066-93-1 566066-94-2 566066-95-3 566066-96-4
566066-97-5 566066-98-6 566066-99-7 566067-00-3 566067-01-4
566067-02-5 566067-03-6 566067-04-7 566067-05-8 566067-06-9
566067-07-0 566067-08-1 566067-09-2 566067-10-5 566067-11-6
566067-12-7 566067-13-8 566067-14-9 566067-15-0 566067-16-1
566067-17-2 566067-18-3 566067-19-4 566067-20-7 566067-22-9
566067-23-0 566067-24-1 566067-25-2 566067-26-3 566067-27-4
566067-28-5 566067-29-6 **566067-30-9** 566067-31-0
566067-32-1 566067-33-2 566067-34-3 566067-35-4 566067-36-5
566067-37-6 566067-38-7 566067-39-8 566067-40-1 566067-41-2
566067-42-3 566067-43-4 566067-44-5 566067-45-6 566067-46-7
566067-47-8 566067-48-9 566067-49-0 566067-50-3 566067-51-4
566067-52-5 566067-53-6 566067-54-7 566067-55-8 566067-56-9
566067-57-0 566067-58-1 566067-59-2 566067-60-5 566067-61-6
566067-62-7 566067-63-8 566067-64-9 566067-65-0 566067-66-1
566067-67-2 566067-68-3 566067-69-4 566067-70-7 566067-71-8
566067-72-9 566067-73-0 566067-74-1 566067-75-2 566067-76-3
566067-77-4 566067-78-5 566067-79-6 566067-80-9 566067-81-0
566067-82-1 566067-83-2 566067-84-3 566067-85-4 566067-86-5
566067-87-6 566067-88-7 566067-89-8 566067-90-1 566067-91-2
566067-92-3 566067-93-4 566067-94-5 566067-95-6 566067-96-7
566067-97-8 566067-98-9 566067-99-0 566068-00-6 566068-01-7
566068-02-8 566068-03-9 566068-04-0 566068-05-1 566068-06-2
566068-07-3 566068-08-4 566068-09-5 566068-10-8 566068-11-9
566068-12-0 566068-13-1 566068-14-2 566068-15-3 566068-16-4
566068-17-5 566068-18-6 566068-19-7 566068-20-0 566068-21-1
566068-22-2 566068-23-3 566068-24-4 566068-25-5 566068-26-6
566068-27-7 566068-28-8 566068-29-9 566068-30-2 566068-31-3
566068-32-4 566068-33-5 566068-34-6 566068-35-7 566068-36-8
566068-37-9 566068-38-0 566068-39-1 566068-40-4 566068-41-5
566068-42-6 566068-43-7 566068-44-8 566068-45-9 566068-46-0
566068-47-1 566068-48-2 566068-49-3, GenBank CAE44821 566068-50-6
566068-51-7 566068-52-8 566068-53-9 566068-54-0 566068-55-1

566068-56-2 566068-57-3 566068-58-4 566068-59-5 566068-60-8,
GenBank CAE44833 566068-61-9 566068-62-0 566068-63-1 566068-64-2
566068-65-3 566068-66-4 566068-67-5 566068-68-6 566068-69-7
566068-70-0 566068-71-1 566068-72-2 566068-73-3 566068-74-4
566068-75-5 566068-76-6 566068-77-7 566068-78-8 566068-79-9
566068-80-2, GenBank CAE44855 566068-81-3, GenBank CAE44856
566068-82-4 566068-83-5 566068-84-6 566068-85-7 566068-86-8
566068-87-9 566068-88-0 566068-89-1 566068-90-4 566068-91-5
566068-92-6 566068-93-7 566068-94-8 566068-95-9 566068-96-0
566068-97-1 566068-98-2 566068-99-3 566069-00-9 566069-01-0
566069-02-1 566069-03-2 566069-04-3 566069-05-4 566069-06-5
566069-07-6 566069-08-7 566069-09-8 566069-10-1 566069-11-2
566069-12-3 566069-13-4 566069-14-5 566069-15-6
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; comparative anal. of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica)

REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:575684 CAPLUS
DOCUMENT NUMBER: 139:302161
TITLE: Dissection of the anti-inflammatory effect of the core and **C-terminal (KPV)** α-melanocyte-stimulating hormone peptides
AUTHOR(S): Getting, Stephen J.; Schioeth, Helgi B.; Perretti, Mauro
CORPORATE SOURCE: The William Harvey Research Institute, London, UK
SOURCE: Journal of Pharmacology and Experimental Therapeutics (2003), 306(2), 631-637
CODEN: JPETAB; ISSN: 0022-3565
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In this study, we analyzed the anti-inflammatory effects of α-MSH (MSH)11-13 (KPV) in comparison with other MSH peptides in a model of crystal-induced peritonitis. Systemic treatment of mice with KPV, α-MSH, the core melanocortin peptide His-Phe-Arg-Trp, and the melanocortin receptor 3/4 agonist Ac-Nle4-c[Asp5,D-Phe7,Lys10]NH2 ACTH4-10 (MTII) but not the selective MC1-R agonist H-Ser-Ser-Ile-Ile-Ser-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 (MS05) resulted in a significant reduction in accumulation of polymorphonuclear leukocyte in the peritoneal cavity. The antimigratory effect of KPV was not blocked by the MC3/4-R antagonist Ac-Nle4-c[Asp5,D-2Nal7,Lys10]NH2 ACTH4-10 (SHU9119). In vitro, macrophage activation, determined as release of KC and interleukin (IL)-1β was inhibited by α-MSH and MTII but not by KPV. Furthermore, macrophage activation by MTII led to an increase in cAMP accumulation, which was attenuated by SHU9119, whereas KPV failed to increase cAMP. The anti-inflammatory properties of KPV were also evident in IL-1β-induced peritonitis inflammation and in mice with a nonfunctional MC1-R (recessive yellow e/e mice). In conclusion, these data highlight that the C-terminal MSH peptide KPV exhibits an anti-inflammatory effect that is clearly different from that of the core MSH peptides. KPV is unlikely to mediate its effects through melanocortin receptors but is more likely to act through inhibition of IL-1β functions.

CC 2-1 (Mammalian Hormones)

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:455013 CAPLUS
DOCUMENT NUMBER: 139:30811
TITLE: Compound and method for the treatment of **sinusitis** with α-MSH peptides having **KPV** motif at **C-terminus**
INVENTOR(S): Catania, Anna P.; Lipton, James M.
PATENT ASSIGNEE(S): Italy
SOURCE: U.S. Pat. Appl. Publ., 37 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003109453	A1	20030612	US 2001-15055	20011210

PRIORITY APPLN. INFO.: US 2001-15055 20011210

AB The invention includes a composition and method of treatment of sinusitis. A preferred embodiment of the invention is a composition for treatment of sinusitis comprising a therapeutically effective amount of one or more peptides selected from the group of peptides with a C-terminal sequence consisting of KPV, HFRWGKPV, and SYSMEHFRWGKPV used in combination with a therapeutically effective amount of an antihistamine/decongestant, corticosteroid, fungicide and/or antibiotic. In yet another embodiment of the invention, one or one or more peptides selected from the group of peptides with a C-terminal sequence consisting of KPV, HFRWGKPV, and SYSMEHFRWGKPV, which may or may not be in combination with therapeutically effective amts. of antibiotics, corticosteroids and/or antihistamine/decongestants, are topically or systemically applied to treat sinusitis.

IC ICM A61K038-00
NCL 514014000
CC 1-7 (Pharmacology)
Section cross-reference(s): 2, 63
ST **sinusitis** treatment KPV peptide; alphaMSH peptide treatment **sinusitis**
IT Peptides, biological studies
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**C-terminal KPV** motif-containing; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)
IT **Protein motifs**
(**KPV**; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)
IT Physiological saline solutions
(as pharmaceutical carrier; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)
IT Gelatins, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as pharmaceutical carrier; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)

IT Drug delivery systems
(carriers; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)
IT Antibiotics
Antihistamines
Decongestants
Fungicides
(in combination; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)
IT Glucocorticoids
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in combination; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)
IT Physiological saline solutions
(phosphate-buffered, as pharmaceutical carrier; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)
IT Conformation
(protein, peptide; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)
IT **Respiratory** tract, **disease**
(**sinusitis**; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)
IT Drug delivery systems
(tablets; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)
IT Spore germination
(α-MSH and peptides inhibition of, of Candida albicans; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)
IT Candida albicans
(α-MSH and peptides inhibition of; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)
IT Neutrophil
(α-MSH enhancement of Candida albicans killing by human; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)
IT Anti-inflammatory agents
(α-MSH peptide as; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)
IT Drug delivery systems
Human
(α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)
IT Interleukin 6
Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α-MSH reduction of production of; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)
IT 82219-24-7
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(Candida albicans response to; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)
IT 57899-96-4 137359-87-6 137359-89-8 137359-90-1

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiinflammatory effects of; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)

IT 9004-32-4, Carboxymethyl cellulose 9004-34-6, Cellulose, biological studies 9004-67-5, Methyl cellulose 9050-36-6, Maltodextrin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as pharmaceutical carrier; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)

IT 50-02-2, Dexamethasone 50-23-7, Hydrocortisone 53-03-2, Prednisone 53-06-5, Cortisone 59-42-7, Phenylephrine 69-53-4, Ampicillin 86-21-5, Pheniramine 86-22-6 90-82-4, Pseudoephedrine 113-92-8, Chlorpheniramine maleate 114-07-8, Erythromycin 124-94-7, Triamcinolone 147-52-4, Nafcillin 378-44-9, Betamethasone 1247-42-3, Methylprednisone 1406-05-9, Penicillin 14838-15-4, Phenylpropanolamine 22916-47-8, Miconazole 26787-78-0, Amoxicillin 27220-47-9, Econazole 51333-22-3, Budesonide 64544-07-6, Cefuroxime axetil 65277-42-1, Ketoconazole 74469-00-4 79794-75-5, Loratidine 81103-11-9, Clarithromycin 83905-01-5, Azithromycin 84625-61-6, Itraconazole 86386-73-4, Fluconazole 87239-81-4, Cefpodoxime proxetil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in combination; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)

IT 67727-97-3
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptide containing **C-terminal**; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)

IT 37353-59-6, Hydroxymethyl cellulose
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(with glycerin, as pharmaceutical carrier; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)

IT 56-81-5, Glycerin, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(with hydroxymethyl cellulose, as pharmaceutical carrier; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)

IT **581-05-5**, α-Melanotropin (swine) **22006-64-0**, α1-13-Corticotropin 37213-49-3, α-MSH **102967-74-8** **296231-52-2** **457605-12-8**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)

IT 137359-88-7
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)

IT 63-42-3, Lactose 134-03-2, Sodium ascorbate 557-04-0, Magnesium stearate 7718-59-4 9003-39-8, Polyvinylpyrrolidone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)

IT 60-92-4, CAMP
RL: BSU (Biological study, unclassified); BIOL (Biological study) (α-MSH peptides in Candida albicans accumulation of; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)

IT 14797-65-0, Nitrite ion, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study) (α-MSH reduction of production of; α-MSH peptides having **KPV** motif at **C-terminus** for treatment of **sinusitis**)

L12 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:778111 CAPLUS
DOCUMENT NUMBER: 137:306624
TITLE: Chimeric genes and starch synthases with heterologous glucan-binding and glycosyltransferase domains and transgenic plants producing altered starch
INVENTOR(S): Commuri, Padma; Keeling, Peter L.; Ramirez, Nona; McKean, Angela; Gao, Zhong; Guan, Hanping
PATENT ASSIGNEE(S): BASF Plant Science G.m.b.H., Germany
SOURCE: PCT Int. Appl., 264 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002079410	A2	20021010	WO 2002-US9574	20020329

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-279720P P 20010330

AB A method for changing glucan chain lengths in any starch- or starch granule-producing organism by using chimeric enzymes containing domains from various starch synthase enzymes is disclosed. This method is based on the discovery that starch synthases are composed of at least two distinct functional domains, i.e., a glucan association domain (GLASS domain) and a catalytic domain, a glycosyl transferase domain (GLYTR domain). Thus, the GLASS domain of granule bound starch synthase (GBSS) may be fused to any other GLYTR domain of another starch synthase enzyme. Chimeric genes which that encode the enzymes and transgenic plants transformed with said constructs are also disclosed. The method of invention can thus be used to provide modified starch granule associated starch synthase enzymes which will catalyze modified amylopectin chain lengths and hence, modified starches. This can be done in any organism and more particularly any plant that stores or synthesizes starch in any of its parts, such as potato, sweet potato, cassava, pea, taro, banana, yam and cereal crops such as rice, maize, wheat, barley, oats, and sorghum. Thus, chimeric genes encoding a fusion of maize GLASS domain to GFP, metallothionein, and

citrate synthase were expressed in maize. All of these fusion proteins were found to be associated with starch granules in the endosperm of the maize kernels. Glucan binding properties of starch synthase enzymes from various plants were determined The starch synthase I enzyme of Basella alba exhibited superior affinity for amylose, amylopectin, glycogen, and starch than did the maize starch synthase I.

IC ICM C12N

CC 7-2 (Enzymes)
Section cross-reference(s): 3, 11

IT **Protein motifs**
(glucan-association domain; chimeric genes and starch synthases with heterologous glucan-binding and glycosyltransferase domains and transgenic plants producing altered starch)

IT **Protein motifs**
(glycosyltransferase domain; chimeric genes and starch synthases with heterologous glucan-binding and glycosyltransferase domains and transgenic plants producing altered starch)

IT **Protein motifs**
(linker domain; chimeric genes and starch synthases with heterologous glucan-binding and glycosyltransferase domains and transgenic plants producing altered starch)

IT 470500-25-5
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(**C-terminal** fragment of maize granule-bound starch synthase; chimeric genes and starch synthases with heterologous glucan-binding and glycosyltransferase domains and transgenic plants producing altered starch)

IT 470500-26-6
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(**C-terminal** fragment of maize starch synthase I; chimeric genes and starch synthases with heterologous glucan-binding and glycosyltransferase domains and transgenic plants producing altered starch)

IT 470500-28-8
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(**C-terminal** fragment of maize starch synthase III; chimeric genes and starch synthases with heterologous glucan-binding and glycosyltransferase domains and transgenic plants producing altered starch)

IT 470500-27-7
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(**C-terminal** fragment of maize starch synthase IIa; chimeric genes and starch synthases with heterologous glucan-binding and glycosyltransferase domains and transgenic plants producing altered starch)

IT 470495-44-4 470495-45-5 470495-46-6 470495-47-7 470495-48-8
470495-49-9 470495-50-2 470495-51-3 470495-52-4 470495-53-5
470495-54-6 470495-55-7 470495-56-8 470495-57-9 470495-58-0
470495-59-1 470495-61-5, Protein (synthetic transit peptide)
470495-62-6 470495-63-7 470495-64-8 470495-65-9 470495-66-0
470495-67-1 470495-68-2 470495-69-3 470495-70-6 470495-71-7
470495-72-8 470495-73-9 470495-74-0 470495-75-1 470495-76-2
470495-77-3 470495-78-4 470495-79-5 470495-80-8 470495-81-9
470495-82-0 **470495-83-1** 470495-84-2 470495-85-3
470495-86-4 470495-87-5 470495-88-6 470495-89-7 **470495-90-0**
470495-91-1 470495-92-2 470495-93-3

470495-94-4 **470495-95-5 470495-96-6**
470495-97-7 470495-98-8 470495-99-9
470496-00-5 **470496-01-6 470496-02-7**
470496-03-8 470496-04-9 470496-05-0
470496-06-1 470496-07-2 470496-08-3, Protein (synthetic linker domain)
470496-09-4, Protein (synthetic linker domain) 470496-10-7, Protein
(synthetic linker domain) 470496-11-8, Protein (synthetic linker domain)
470496-12-9, Protein (synthetic linker domain) 470496-13-0, Protein
(synthetic linker domain) 470496-14-1, Protein (synthetic linker domain)
470496-15-2, Protein (synthetic linker domain) 470496-16-3, Protein
(synthetic linker domain) 470496-17-4, Protein (synthetic linker domain)
470496-18-5, Protein (synthetic linker domain) 470496-19-6, Protein
(synthetic linker domain) 470496-20-9, Protein (synthetic linker domain)
470496-21-0, Protein (synthetic linker domain) 470496-22-1, Protein
(synthetic linker domain) 470496-23-2, Protein (synthetic linker domain)
470496-24-3, Protein (synthetic linker domain) 470496-25-4, Protein
(synthetic linker domain) 470496-26-5, Protein (synthetic linker domain)
470496-27-6, Protein (synthetic linker domain) 470496-28-7, Protein
(synthetic linker domain) 470496-29-8, Protein (synthetic linker domain)
470496-30-1, Protein (synthetic linker domain) 470496-31-2, Protein
(synthetic linker domain) 470496-32-3, Protein (synthetic linker domain)
470496-33-4, Protein (synthetic linker domain) 470496-34-5, Protein
(synthetic linker domain) 470496-35-6, Protein (synthetic linker domain)
470496-36-7, Protein (synthetic linker domain) 470496-37-8, Protein
(synthetic linker domain) 470496-38-9, Protein (synthetic linker domain)
470496-39-0, Protein (synthetic linker domain) 470496-40-3, Protein
(synthetic linker domain) 470496-41-4, Protein (synthetic linker domain)
470496-42-5, Protein (synthetic linker domain) 470496-43-6, Protein
(synthetic linker domain) 470496-44-7, Protein (synthetic linker domain)
470496-45-8, Protein (synthetic linker domain) 470496-46-9 470496-47-0
470496-48-1 470496-49-2 470496-50-5 470496-51-6 470496-52-7
470496-53-8 470496-54-9 470496-55-0 470496-56-1 470496-57-2
470496-58-3 470496-59-4 470496-60-7 470496-61-8 470496-62-9
470496-63-0 470496-64-1 470496-65-2 470496-66-3 470496-67-4
470496-68-5 470496-69-6 470496-70-9 470496-71-0 470496-72-1
470496-73-2 470496-74-3 470496-75-4 470496-76-5 470496-77-6
470496-78-7 470496-79-8 470496-80-1 470496-81-2 470496-82-3
470496-83-4 470496-84-5 470496-85-6 470496-86-7 470496-87-8
470496-88-9 470496-89-0 470496-90-3, Protein (synthetic **C-**
terminal fragment) 470496-91-4, Protein (synthetic **C-**
terminal fragment) 470496-92-5, Protein (synthetic **C-**
terminal fragment) 470496-93-6, Protein (synthetic **C-**
terminal fragment) 470496-94-7, Protein (synthetic **C-**
terminal fragment) 470496-95-8, Protein (synthetic **C-**
terminal fragment) 470496-96-9, Protein (synthetic **C-**
terminal fragment) 470496-97-0, Protein (synthetic **C-**
terminal fragment) 470496-98-1, Protein (synthetic **C-**
terminal fragment) 470496-99-2, Protein (synthetic **C-**
terminal fragment) 470497-00-8, Protein (synthetic **C-**
terminal fragment) 470497-01-9, Protein (synthetic **C-**
terminal fragment) 470497-21-3 470497-22-4, Protein (synthetic
transit peptide) 470497-23-5, Protein (synthetic transit peptide)
470497-24-6, Protein (synthetic transit peptide) 470497-25-7
470497-26-8 470497-27-9 470497-28-0 470497-29-1 470497-30-4
470497-31-5 470497-32-6 470497-33-7 470497-34-8 470497-35-9
470497-36-0 470497-37-1 470497-38-2 470497-39-3 470497-40-6
470497-41-7 470497-42-8 470497-43-9 470497-44-0 470497-45-1
470497-46-2 470497-47-3 470497-48-4 470497-49-5 470497-50-8
470497-51-9 470497-52-0 470497-53-1 470497-54-2 470497-55-3
470497-56-4 470497-57-5 470497-58-6 470497-59-7 470497-60-0

470497-61-1 470497-62-2 470497-63-3 470497-64-4 470497-65-5
470497-66-6 470497-67-7, Protein (synthetic linker domain)
470497-68-8, Protein (synthetic linker domain) 470497-69-9, Protein
(synthetic linker domain) 470497-70-2, Protein (synthetic linker domain)
470497-71-3, Protein (synthetic linker domain) 470497-72-4, Protein
(synthetic linker domain) 470497-73-5, Protein (synthetic linker domain)
470497-74-6, Protein (synthetic linker domain) 470497-75-7, Protein
(synthetic linker domain) 470497-76-8, Protein (synthetic linker domain)
470497-77-9, Protein (synthetic linker domain) 470497-78-0, Protein
(synthetic linker domain) 470497-79-1, Protein (synthetic linker domain)
470497-80-4, Protein (synthetic linker domain) 470497-81-5, Protein
(synthetic linker domain) 470497-82-6, Protein (synthetic linker domain)
470497-83-7, Protein (synthetic linker domain) 470497-84-8, Protein
(synthetic linker domain) 470497-85-9, Protein (synthetic linker domain)
470497-86-0, Protein (synthetic linker domain) 470497-87-1, Protein
(synthetic linker domain) 470497-88-2, Protein (synthetic linker domain)
470497-89-3, Protein (synthetic linker domain) 470497-90-6, Protein
(synthetic linker domain) 470497-91-7, Protein (synthetic linker domain)
470497-92-8, Protein (synthetic linker domain) 470497-93-9, Protein
(synthetic linker domain) 470497-94-0, Protein (synthetic linker domain)
470497-95-1, Protein (synthetic linker domain) 470497-96-2, Protein
(synthetic linker domain) 470497-97-3, Protein (synthetic linker domain)
470497-98-4, Protein (synthetic linker domain) 470497-99-5, Protein
(synthetic linker domain) 470498-00-1, Protein (synthetic linker domain)
470498-01-2, Protein (synthetic linker domain)
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)
(amino acid sequence; chimeric genes and starch synthases with
heterologous glucan-binding and glycosyltransferase domains and
transgenic plants producing altered starch)

IT 470498-02-3 470498-03-4 470498-04-5 470498-05-6 470498-06-7
470498-07-8 470498-08-9 470498-09-0 470498-10-3 470498-11-4
470498-12-5 470498-13-6 470498-14-7 470498-15-8 470498-16-9
470498-17-0 470498-18-1 470498-19-2 470498-20-5 470498-21-6
470498-22-7 470498-23-8 470498-24-9 470498-25-0 470498-26-1
470498-27-2 470498-28-3 470498-29-4 470498-30-7 470498-31-8
470498-32-9 470498-33-0 470498-34-1 470498-35-2 470498-36-3
470498-37-4 470498-38-5 470498-39-6 470498-40-9 470498-41-0
470498-42-1 470498-43-2, Protein (synthetic **C-terminal**
fragment) 470498-44-3, Protein (synthetic **C-terminal**
fragment) 470498-45-4, Protein (synthetic **C-terminal**
fragment) 470498-46-5, Protein (synthetic **C-terminal**
fragment) 470498-47-6, Protein (synthetic **C-terminal**
fragment) 470498-48-7, Protein (synthetic **C-terminal**
fragment) 470498-49-8, Protein (synthetic **C-terminal**
fragment) 470498-50-1, Protein (synthetic **C-terminal**
fragment) 470498-51-2, Protein (synthetic **C-terminal**
fragment) 470498-52-3, Protein (synthetic **C-terminal**
fragment) 470498-53-4, Protein (synthetic **C-terminal**
fragment) 470498-54-5, Protein (synthetic **C-terminal**
fragment) 470498-55-6, Protein (synthetic **C-terminal**
fragment) 470498-83-0 470498-84-1 470498-85-2 470498-86-3
470498-87-4 470498-88-5 470498-89-6 470498-90-9 470498-91-0
470498-92-1 470498-93-2 470498-94-3 470498-95-4 470498-96-5
470498-97-6 470498-98-7 470498-99-8 470499-00-4 470499-01-5
470499-02-6 470499-03-7 470499-04-8 470499-05-9 470499-06-0
470499-07-1 470499-08-2 470499-09-3 470499-10-6 470499-11-7
470499-12-8 470499-13-9 470499-14-0 470499-15-1 470499-16-2
470499-17-3 470499-18-4 470499-19-5 470499-20-8 470499-21-9
470499-22-0 470499-23-1 470499-24-2 470499-25-3 470499-26-4

470499-27-5 470499-28-6 470499-29-7 470499-30-0 470499-31-1
470499-32-2 470499-33-3 470499-34-4 470499-35-5 470499-36-6
470499-37-7 470499-38-8 470499-39-9 470499-40-2 470499-41-3
470499-42-4 470499-43-5 470499-44-6 470499-45-7 470499-46-8
470499-47-9 470499-48-0 470499-49-1 470499-50-4 470499-51-5
470499-52-6 470499-53-7 470499-54-8 470499-55-9 470499-56-0
470499-57-1 470499-58-2 470499-59-3 470499-60-6 470499-61-7
470499-62-8 470499-63-9 470499-64-0 470499-65-1 470499-66-2
470499-67-3 470499-68-4 470499-69-5 470499-70-8 470499-71-9
470499-72-0 470499-73-1 470499-74-2 470499-75-3 470499-76-4
470499-77-5, Protein (synthetic **C-terminal** fragment)
470499-78-6, Protein (synthetic **C-terminal** fragment)
470499-79-7, Protein (synthetic **C-terminal** fragment)
470499-80-0, Protein (synthetic **C-terminal** fragment)
470499-81-1, Protein (synthetic **C-terminal** fragment)
470499-82-2, Protein (synthetic **C-terminal** fragment)
470499-83-3 470499-84-4 470499-85-5, Protein (synthetic **C-terminal** fragment) 470499-86-6 470499-87-7 470499-88-8
470499-89-9 470499-90-2 470499-91-3 470499-92-4 470499-93-5
470499-94-6 470499-95-7 470499-96-8 470499-97-9 470499-98-0
470499-99-1 470500-00-6 470500-01-7 470500-02-8 470500-03-9
470500-04-0 470500-05-1 470500-06-2 470500-07-3 470500-08-4
470500-09-5 470500-10-8 470500-11-9 470500-12-0 470500-13-1
470500-14-2 470500-15-3 470500-16-4 470500-17-5 470500-18-6
470500-19-7 470500-29-9, Protein (synthetic linker domain)
470500-30-2, Protein (synthetic linker domain) 470500-31-3, Protein (synthetic linker domain) 470500-32-4, Protein (synthetic linker domain)
470500-33-5, Protein (synthetic linker domain) 470500-34-6, Protein (synthetic linker domain) 470500-35-7, Protein (synthetic linker domain)
470500-36-8, Protein (synthetic linker domain) 470500-37-9, Protein (synthetic linker domain) 470500-38-0, Protein (synthetic linker domain)
470500-39-1, Protein (synthetic linker domain) 470500-40-4, Protein (synthetic linker domain) 470500-41-5, Protein (synthetic linker domain)
470500-42-6, Protein (synthetic linker domain) 470500-43-7, Protein (synthetic linker domain) 470500-44-8, Protein (synthetic linker domain)
470500-45-9, Protein (synthetic linker domain) 470500-46-0, Protein (synthetic linker domain) 470500-47-1, Protein (synthetic linker domain)
470500-48-2, Protein (synthetic linker domain) 470500-49-3, Protein (synthetic linker domain) 470500-50-6, Protein (synthetic linker domain)
470500-51-7, Protein (synthetic linker domain) 470500-52-8, Protein (synthetic linker domain) 470500-53-9, Protein (synthetic linker domain)
470500-54-0, Protein (synthetic linker domain) 470500-55-1, Protein (synthetic linker domain) 470500-56-2, Protein (synthetic linker domain)
470500-57-3, Protein (synthetic linker domain) 470500-58-4, Protein (synthetic linker domain) 470500-59-5, Protein (synthetic linker domain)
470500-60-8, Protein (synthetic linker domain) 470500-61-9, Protein (synthetic linker domain) 470500-62-0, Protein (synthetic linker domain)
470500-63-1, Protein (synthetic linker domain) 470500-64-2, Protein (synthetic linker domain) 470500-65-3, Protein (synthetic linker domain)
470500-66-4, Protein (synthetic linker domain) 470500-67-5, Protein (synthetic linker domain) 470500-68-6, Protein (synthetic linker domain)
470500-69-7, Protein (synthetic linker domain) 470500-70-0, Protein (synthetic linker domain) 470500-71-1 470725-61-2
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; chimeric genes and starch synthases with heterologous glucan-binding and glycosyltransferase domains and transgenic plants producing altered starch)

IT 470494-37-2
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

(Biological study)
(maize granule-bound starch synthase **C-terminal** fragment; chimeric genes and starch synthases with heterologous glucan-binding and glycosyltransferase domains and transgenic plants producing altered starch)

IT 470468-13-4
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(maize starch synthase I **C-terminal** fragment; chimeric genes and starch synthases with heterologous glucan-binding and glycosyltransferase domains and transgenic plants producing altered starch)

IT 470467-93-7 470467-94-8 470467-95-9 470467-96-0 470467-97-1
470467-98-2 470467-99-3 470468-00-9 470468-01-0 470468-02-1
470468-03-2 470468-04-3 470468-05-4 470468-06-5 470468-07-6
470468-08-7 470468-09-8 470468-14-5 470468-15-6 470468-16-7
470468-26-9 470494-38-3 470494-39-4 470494-40-7 470498-56-7
470498-57-8 470498-58-9 470498-59-0 470498-60-3 470498-61-4
470498-62-5 470498-63-6 470498-64-7 470498-65-8 470498-66-9
470498-67-0 470498-68-1 470498-69-2 470498-70-5 470498-71-6
470498-72-7 470498-73-8 470498-74-9
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(protein **C-terminal** fragment; chimeric genes and starch synthases with heterologous glucan-binding and glycosyltransferase domains and transgenic plants producing altered starch)

L12 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1988:466889 CAPLUS
DOCUMENT NUMBER: 109:66889
TITLE: ACTH fragments for the treatment of shock and respiratory and cardiovascular insufficiency
INVENTOR(S): Bertolini, Alfio
PATENT ASSIGNEE(S): Italy
SOURCE: Eur. Pat. Appl., 7 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 232697	A2	19870819	EP 1987-100016	19870102
EP 232697	A3	19900523		
EP 232697	B1	19930728		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 4794104	A	19881227	US 1987-183	19870102
AT 91900	E	19930815	AT 1987-100016	19870102
ES 2058065	T3	19941101	ES 1987-100016	19870102
JP 62215531	A2	19870922	JP 1987-1574	19870107
ZA 8700246	A	19870930	ZA 1987-246	19870114
PRIORITY APPLN. INFO.:			IT 1986-19086	19860115
			EP 1987-100016	19870102

AB The polypeptides selected from a) a fragment of ACTH (1-39) of formula ACTH (x-y) [X = 1-5, Y = 10-39, not ACTH (1-24)]; b) the N-acyl and N,O-diacyl derivs. of ACTH (x-y); or c) 4-norleucine-7-D-phenylalanine-α-MSH are used for treatment of shock and respiratory or cardiovascular insufficiencies. Rats were bled of 2-2.5 mL/100 g blood

(≥50% blood volume) and immediately administered bolus 160 μg/kg i.v. ACTH (1-16). Prior to bleeding, mean arterial pressure was 78.25 ± 12.46 mmHg; immediately after bleeding, 15.50 ± 2.53; and 15-30 min after treatment, 54.50 ± 2.02; and no rats were dead 120 min after treatment. For control rats, blood pressure was essentially unchanged 30 min after bleeding, and all the rats were dead 120 min after treatment.

IC ICM A61K037-02
CC 1-8 (Pharmacology)
IT Cardiovascular system
Respiratory tract
(**disease**, treatment of, ACTH fragments for)
IT **75921-69-6**
RL: BIOL (Biological study)
(pharmaceutical containing ACTH fragments and, for treatment of shock conditions)
IT 1285-85-4, α1-18-Corticotropin 1285-85-4D, α1-18-Corticotropin, N-acylated and N,O-diacylated derivs. 4037-01-8, ACTH (4-10) 4037-01-8D, ACTH (4-10), N-acylated and N,O-diacylated derivs. 5576-42-1, ACTH (1-16) 5576-42-1D, ACTH (1-16), N-acylated and N,O-diacylated derivs. 7266-47-9, ACTH (1-17) 7266-47-9D, ACTH (1-17), N-acylated and N,O-diacylated derivs.. 9061-27-2, α1-39-Corticotropin (pig) 9061-27-2D, α1-39-Corticotropin (pig), fragments **22006-64-0**, ACTH (1-13) **22006-64-0D**, ACTH (1-13), N-acylated and N,O-diacylated derivs. **115594-30-4** **115594-30-4D**, N-acylated and N,O-diacylated derivs.
RL: BIOL (Biological study)
(treatment of shock and respiratory and cardiovascular insufficiency by)

=> select rn l12 1-7 hit
E57 THROUGH E84 ASSIGNED

=> fil reg

FILE 'REGISTRY' ENTERED AT 11:45:05 ON 26 FEB 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 FEB 2004 HIGHEST RN 654050-72-3
DICTIONARY FILE UPDATES: 24 FEB 2004 HIGHEST RN 654050-72-3

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> s e57-84
1 22006-64-0/BI

(22006-64-0/RN)
1 115594-30-4/BI
(115594-30-4/RN)
1 102967-74-8/BI
(102967-74-8/RN)
1 296231-52-2/BI
(296231-52-2/RN)
1 457605-12-8/BI
(457605-12-8/RN)
1 470495-83-1/BI
(470495-83-1/RN)
1 470495-90-0/BI
(470495-90-0/RN)
1 470495-91-1/BI
(470495-91-1/RN)
1 470495-92-2/BI
(470495-92-2/RN)
1 470495-93-3/BI
(470495-93-3/RN)
1 470495-95-5/BI
(470495-95-5/RN)
1 470495-96-6/BI
(470495-96-6/RN)
1 470495-97-7/BI
(470495-97-7/RN)
1 470495-98-8/BI
(470495-98-8/RN)
1 470495-99-9/BI
(470495-99-9/RN)
1 470496-01-6/BI
(470496-01-6/RN)
1 470496-02-7/BI
(470496-02-7/RN)
1 470496-03-8/BI
(470496-03-8/RN)
1 470496-04-9/BI
(470496-04-9/RN)
1 470496-05-0/BI
(470496-05-0/RN)
1 565118-79-8/BI
(565118-79-8/RN)
1 565136-80-3/BI
(565136-80-3/RN)
1 566066-08-8/BI
(566066-08-8/RN)
1 566067-30-9/BI
(566067-30-9/RN)
1 566103-01-3/BI
(566103-01-3/RN)
1 566132-47-6/BI
(566132-47-6/RN)
1 581-05-5/BI
(581-05-5/RN)
1 75921-69-6/BI
(75921-69-6/RN)

L13 28 (22006-64-0/BI OR 115594-30-4/BI OR 102967-74-8/BI OR 296231-52-2/BI OR 457605-12-8/BI OR 470495-83-1/BI OR 470495-90-0/BI OR 470495-91-1/BI OR 470495-92-2/BI OR 470495-93-3/BI OR 470495-95-5/BI OR 470495-96-6/BI OR 470495-97-7/BI OR 470495-98-8/BI OR 470495-99-9/BI OR 470496-01-6/BI OR 470496-02-7/BI OR 470496-03-

8/BI OR 470496-04-9/BI OR 470496-05-0/BI OR 565118-79-8/BI OR 565136-80-3/BI OR 566066-08-8/BI OR 566067-30-9/BI OR 566103-01-3/BI OR 566132-47-6/BI OR 581-05-5/BI OR 75921-69-6/BI)

=> s l2 and l13
L14 28 L2 AND L13

=> => d ide can sql

L14 ANSWER 1 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **566132-47-6** REGISTRY
CN Ferredoxin (Bordetella bronchiseptica strain RB50 gene BB4649) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank CAE35011
CN GenBank CAE35011 (Translated from: GenBank BX640451)
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
SQL 101

REFERENCE 1: 139:208598

=> d ide can sql 2-28

L14 ANSWER 2 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **566103-01-3** REGISTRY
CN Ferredoxin (Bordetella parapertussis strain 12822 gene BPP4179) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank CAE39458
CN GenBank CAE39458 (Translated from: GenBank BX640435)
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
SQL 101

REFERENCE 1: 139:208597

L14 ANSWER 3 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **566067-30-9** REGISTRY

CN Ferredoxin (Bordetella pertussis strain Tohama I gene BP0353) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank CAE44685
CN GenBank CAE44685 (Translated from: GenBank BX640412)
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
SQL 101

REFERENCE 1: 139:208590

L14 ANSWER 4 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **566066-08-8** REGISTRY
CN 3-Hydroxybutyryl-CoA dehydrogenase (Bordetella pertussis strain Tohama I gene BP0217) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank CAE40597
CN GenBank CAE40597 (Translated from: GenBank BX640411)
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
SQL 310

REFERENCE 1: 139:208590

L14 ANSWER 5 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **565136-80-3** REGISTRY
CN 3-Hydroxybutyryl-CoA dehydrogenase (Bordetella bronchiseptica strain RB50 gene BB0418) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank CAE30916
CN GenBank CAE30916 (Translated from: GenBank BX640438)
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
SQL 310

REFERENCE 1: 139:208598

L14 ANSWER 6 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **565118-79-8** REGISTRY
CN 3-Hydroxybutyryl-CoA dehydrogenase (Bordetella parapertussis strain 12822 gene BPP0416) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank CAE36000
CN GenBank CAE36000 (Translated from: GenBank BX640424)
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
SQL 354

REFERENCE 1: 139:208597

L14 ANSWER 7 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **470496-05-0** REGISTRY
CN Protein (synthetic glucan-association domain) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 233: PN: WO02079410 SEQID: 524 claimed protein
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
SQL 222

REFERENCE 1: 137:306624

L14 ANSWER 8 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **470496-04-9** REGISTRY
CN Protein (synthetic glucan-association domain) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 232: PN: WO02079410 SEQID: 523 claimed protein
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
SQL 225

REFERENCE 1: 137:306624

L14 ANSWER 9 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **470496-03-8** REGISTRY
CN Protein (synthetic glucan-association domain) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 231: PN: WO02079410 SEQID: 522 claimed protein
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
SQL 222

REFERENCE 1: 137:306624

L14 ANSWER 10 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **470496-02-7** REGISTRY
CN Protein (synthetic glucan-association domain) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 230: PN: WO02079410 SEQID: 521 claimed protein
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
SQL 221

REFERENCE 1: 137:306624

L14 ANSWER 11 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **470496-01-6** REGISTRY
CN Protein (synthetic glucan-association domain) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 229: PN: WO02079410 SEQID: 520 claimed protein
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
SQL 222

REFERENCE 1: 137:306624

L14 ANSWER 12 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN

RN **470495-99-9** REGISTRY
CN Protein (synthetic glucan-association domain) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 227: PN: WO02079410 SEQID: 518 claimed protein
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
SQL 218

REFERENCE 1: 137:306624

L14 ANSWER 13 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **470495-98-8** REGISTRY
CN Protein (synthetic glucan-association domain) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 226: PN: WO02079410 SEQID: 517 claimed protein
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
SQL 218

REFERENCE 1: 137:306624

L14 ANSWER 14 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **470495-97-7** REGISTRY
CN Protein (synthetic glucan-association domain) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 225: PN: WO02079410 SEQID: 516 claimed protein
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
SQL 218

REFERENCE 1: 137:306624

L14 ANSWER 15 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **470495-96-6** REGISTRY
CN Protein (synthetic glucan-association domain) (9CI) (CA INDEX NAME)
OTHER NAMES:

CN 223: PN: WO02079410 SEQID: 514 claimed protein
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
SQL 218

REFERENCE 1: 137:306624

L14 ANSWER 16 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **470495-95-5** REGISTRY
CN Protein (synthetic glucan-association domain) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 222: PN: WO02079410 SEQID: 513 claimed protein
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
SQL 233

REFERENCE 1: 137:306624

L14 ANSWER 17 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **470495-93-3** REGISTRY
CN Protein (synthetic glucan-association domain) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 220: PN: WO02079410 SEQID: 511 claimed protein
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
SQL 227

REFERENCE 1: 137:306624

L14 ANSWER 18 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **470495-92-2** REGISTRY
CN Protein (synthetic glucan-association domain) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 219: PN: WO02079410 SEQID: 510 claimed protein
FS PROTEIN SEQUENCE
MF Unspecified

CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
SQL 219

REFERENCE 1: 137:306624

L14 ANSWER 19 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **470495-91-1** REGISTRY
CN Protein (synthetic glucan-association domain) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 218: PN: WO02079410 SEQID: 509 claimed protein
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
SQL 218

REFERENCE 1: 137:306624

L14 ANSWER 20 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **470495-90-0** REGISTRY
CN Protein (synthetic glucan-association domain) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 217: PN: WO02079410 SEQID: 508 claimed protein
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
SQL 217

REFERENCE 1: 137:306624

L14 ANSWER 21 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **470495-83-1** REGISTRY
CN Protein (synthetic glucan-association domain) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 210: PN: WO02079410 SEQID: 500 claimed protein
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
SQL 246

REFERENCE 1: 137:306624

L14 ANSWER 22 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **457605-12-8** REGISTRY
CN L-Valinamide, N-acetyl-L-cysteinyl-L-lysyl-L-prolyl-, bimol. (1→1')-disulfide (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 14: PN: WO03051390 PAGE: 57 claimed protein
CN 2: PN: US20030109453 SEQID: 2 claimed protein
CN 5: PN: US20030223949 SEQID: 5 claimed protein
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C42 H74 N12 O10 S2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

SQL 8,4,4

REFERENCE 1: 140:1183

REFERENCE 2: 139:63360

REFERENCE 3: 139:30811

REFERENCE 4: 137:222061

L14 ANSWER 23 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **296231-52-2** REGISTRY
CN L-Valine, L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophylglycyl-L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 12: PN: WO03051390 PAGE: 57 claimed protein
CN 1: PN: WO03020223 SEQID: 3 unclaimed sequence
CN 3: PN: US20030109453 SEQID: 3 claimed protein
CN 3: PN: US20030223949 SEQID: 3 claimed protein
CN 3: PN: WO02080858 SEQID: 3 claimed protein
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C50 H71 N15 O9
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



9 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
9 REFERENCES IN FILE CAPLUS (1907 TO DATE)

SQL 8

REFERENCE 1: 140:87665

REFERENCE 2: 140:1183

REFERENCE 3: 139:63360

REFERENCE 4: 139:30811

REFERENCE 5: 137:304809

REFERENCE 6: 137:222061

REFERENCE 7: 137:179875

REFERENCE 8: 133:261952

REFERENCE 9: 133:261547

L14 ANSWER 24 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **115594-30-4** REGISTRY
CN L-Valine, N-[1-[N2-[N-[N-[N2-[N-(N-L-α-glutamyl-L-histidyl)-L-phenylalanyl]-L-arginyl]-L-tryptophyl]glycyl]-L-lysyl]-L-prolyl]- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C55 H78 N16 O12
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

SQL 9

REFERENCE 1: 109:66889

L14 ANSWER 25 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **102967-74-8** REGISTRY
CN L-Valinamide, N-acetyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophylglycyl-L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 54: PN: US20030109453 SEQID: 53 claimed protein
CN Ac-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C52 H74 N16 O9
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

SQL 8

REFERENCE 1: 139:30811

REFERENCE 2: 133:261952

REFERENCE 3: 133:261547

REFERENCE 4: 113:17963

REFERENCE 5: 105:18672

L14 ANSWER 26 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **75921-69-6** REGISTRY
CN α-Melanotropin (swine), 4-L-norleucine-7-D-phenylalanine- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN α-Melanotropin (pig), 4-L-norleucine-7-D-phenylalanine-
OTHER NAMES:
CN MBJ 05
CN Melanotan I
CN Melanotan-1
CN [Nle4,D-Phe7]-α-MSH
CN [Nle4-D-Phe7]-α-Melanocyte-stimulating hormone
FS PROTEIN SEQUENCE; STEREOSEARCH
DR 162112-36-9, 103088-28-4, 272781-22-3
MF C78 H111 N21 O19
LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CANCERLIT, CAPLUS, CHEMCATS, CSCHEM, DDFU, DRUGU, IPA, MEDLINE, RTECS*, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



260 REFERENCES IN FILE CA (1907 TO DATE)
10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
261 REFERENCES IN FILE CAPLUS (1907 TO DATE)

SQL 13

REFERENCE 1: 140:122998

REFERENCE 2: 140:71535

REFERENCE 3: 140:1183

REFERENCE 4: 139:361895

REFERENCE 5: 139:346169

REFERENCE 6: 139:346168

REFERENCE 7: 139:346159

REFERENCE 8: 139:317762

REFERENCE 9: 139:271172

REFERENCE 10: 139:240512

L14 ANSWER 27 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **22006-64-0** REGISTRY
CN α1-13-Corticotropin (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN α-Melanotropin (Lepisosteus osseus)
CN α-Melanotropin (Pelodiscus sinensis)
CN α-Melanotropin (pig), N-deacetyl-13-L-valine-
CN α-Melanotropin (Protopterus annectens pituitary gland)
CN α-MSH (Lepisosteus osseus)
CN α1-13-ACTH
CN β1-13-ACTH
CN 11: PN: CN1293205 PAGE: 5 unclaimed sequence
CN 13: PN: WO0223184 SEQID: 8 unclaimed sequence
CN 13: PN: WO03051390 PAGE: 57 claimed protein
CN 14: PN: WO0210195 PAGE: 61 claimed sequence
CN 19: PN: JP2002330789 PAGE: 2 claimed sequence
CN 1: PN: WO0206316 PAGE: 26 claimed sequence
CN 24: PN: US6110889 SEQID: 55 unclaimed sequence
CN 25: PN: WO0069900 SEQID: 26 unclaimed sequence
CN 26: PN: WO0069900 SEQID: 27 unclaimed sequence
CN 28: PN: WO0069900 SEQID: 29 unclaimed sequence

CN 2: PN: WO03020223 SEQID: 4 unclaimed sequence
CN 3: PN: WO0004873 SEQID: 3 claimed protein
CN 41: PN: WO03066080 SEQID: 41 unclaimed sequence
CN 4: PN: US20030109453 SEQID: 4 claimed protein
CN 4: PN: US20030212002 TABLE: 2 unclaimed sequence
CN 4: PN: US20030223949 SEQID: 4 claimed protein
CN 4: PN: WO02080858 SEQID: 4 claimed protein
CN 5: PN: US20020193332 PAGE: 4 unclaimed sequence
CN 5: PN: WO0069900 SEQID: 4 unclaimed sequence
CN 7: PN: US20030166570 SEQID: 1 unclaimed sequence
CN ACTH1-13
FS PROTEIN SEQUENCE; STEREOSEARCH
DR 17088-02-7
MF C75 H106 N20 O19 S
LC STN Files: BIOSIS, CA, CANCERLIT, CAPLUS, CHEMCATS, CSCHEM, DDFU, DRUGU, EMBASE, MEDLINE, TOXCENTER, USPAT2, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B

66 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
66 REFERENCES IN FILE CAPLUS (1907 TO DATE)

SQL 13

REFERENCE 1: 140:87665

REFERENCE 2: 140:1183

REFERENCE 3: 139:375031

REFERENCE 4: 139:265867

REFERENCE 5: 139:207828

REFERENCE 6: 139:173813

REFERENCE 7: 139:63360

REFERENCE 8: 139:48854

REFERENCE 9: 139:30971

REFERENCE 10: 139:30811

L14 ANSWER 28 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **581-05-5** REGISTRY
CN α-Melanotropin (swine) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN α-Melanocyte-stimulating hormone (8CI)
CN α-Melanotropin (pig)
CN Valinamide, acetyl-L-seryl-L-tyrosyl-L-seryl-L-methionyl-L-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophylglycyl-L-lysyl-L-prolyl-, L- (7CI)
OTHER NAMES:
CN α-Melanotropin (Acipenser transmontanus)
CN α-Melanotropin (camel)
CN α-Melanotropin (camel), N-acetyl-13-L-valinamide-
CN α-Melanotropin (horse)
CN α-Melanotropin (human)
CN α-Melanotropin (Macaca nemestrina)
CN α-Melanotropin (monkey)
CN α-Melanotropin (Mustela vison)
CN α-Melanotropin (ox)
CN α-Melanotropin (Rana ridibunda perezii)
CN α-Melanotropin (sheep)
CN α-Melanotropin (Thunnus obesus)
CN α-Melanotropin (tuna)
CN α-Melanotropin I (Oncorhynchus keta)
CN α-MSH
CN α-MSH (pig)
CN α-MSH (Rana ridibunda)
CN α-MSH I (Oncorhynchus keta)
CN α-MSH I (salmon)
CN α-N-acetyl-ACTH(1-13)-NH2
CN α-N-Acetyl-ACTH-1-13-amide
CN α1-13-Corticotropin, N-acetyl-13-L-valinamide-
CN 53: PN: US20030109453 SEQID: 52 claimed protein
CN ACTH fragment analog
CN Ba 33761
CN L-Valinamide, N-acetyl-L-seryl-L-tyrosyl-L-seryl-L-methionyl-L-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophylglycyl-L-lysyl-L-prolyl-
CN N-Acetyl-ACTH(1-13)-amide
CN N-Acetyl-ACTH-(1-13)-NH2
CN PN: WO9954358 SEQID: 1 claimed protein
FS PROTEIN SEQUENCE; STEREOSEARCH
DR 17107-62-9, 4353-59-7
MF C77 H109 N21 O19 S
CI COM
LC STN Files: ADISNEWS, AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, MEDLINE, PROMT, TOXCENTER, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



371 REFERENCES IN FILE CA (1907 TO DATE)
29 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
371 REFERENCES IN FILE CAPLUS (1907 TO DATE)
6 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

SQL 13

REFERENCE 1: 140:71535

REFERENCE 2: 139:346163

REFERENCE 3: 139:317762

REFERENCE 4: 139:302161

REFERENCE 5: 139:235015

REFERENCE 6: 139:226524

REFERENCE 7: 139:95624

REFERENCE 8: 139:95623

REFERENCE 9: 139:30971

REFERENCE 10: 139:30811

=>

exact Structural search

Teller 10/015055

=> fli reg
FLI IS NOT A RECOGNIZED COMMAND

=> fil reg
FILE 'REGISTRY' ENTERED AT 14:23:24 ON 26 FEB 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 FEB 2004 HIGHEST RN 654632-96-9
DICTIONARY FILE UPDATES: 25 FEB 2004 HIGHEST RN 654632-96-9

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d que stat l2
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
L2 5 SEA FILE=REGISTRY FAM FUL L1

Page 1 searched by Alex Waclawiw

100.0% PROCESSED 5775 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.01

=> fil caplus
FILE 'CAPLUS' ENTERED AT 14:23:32 ON 26 FEB 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 26 Feb 2004 VOL 140 ISS 9
FILE LAST UPDATED: 25 Feb 2004 (20040225/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d que nos l6
L1 STR
L2 5 SEA FILE=REGISTRY FAM FUL L1
L3 43 SEA FILE=CAPLUS ABB=ON PLU=ON L2
L4 1 SEA FILE=CAPLUS ABB=ON PLU=ON L3 AND (RESPIR?/OBI OR SINUS?/OBI)
L5 8 SEA FILE=CAPLUS ABB=ON PLU=ON L3 AND 63/SX,SC → pharmaceuticals
L6 8 SEA FILE=CAPLUS ABB=ON PLU=ON L5 OR L4

=> d .ca hitstr l6 1-8

L6 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:39600 CAPLUS
DOCUMENT NUMBER: 140:87665
TITLE: Treatment of ophthalmic conditions
INVENTOR(S): Lipton, James M.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U.S. Provisional Ser. No. 382,887.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004009181	A1	20040115	US 2002-298142	20021115

US 2004033955 A1 20040219 US 2003-442683 20030521
PRIORITY APPLN. INFO.: US 2002-382887P P 20020521

AB The present invention discloses a method of treating ophthalmic conditions by administering to a vertebrate inflicted with the condition a therapeutically effective amount of a peptide which is derived from alpha-MSH (α-MSH) and biol. functional equivalent thereof. Specifically, the peptides derived from alpha-MSH (α-MSH) include α-MSH (1-13) which is SYSMEHFRWGKPV (SEQ. ID NO. 4), α-MSH (4-10) which is MEHFRWG (SEQ. ID NO. 2), α-MSH (6-13) which is HFRWGKPV (SEQ. ID NO. 3), α-MSH (11-13) which is KPV (SEQ. ID NO. 1), and a KPV dimer (SEQ. ID NO. 5). The ophthalmic condition can be the result of an on going insult such as "Computer Eyes" or an acute or chronic infection of the eyes. The infective organism can be caused by a microorganism, which includes a bacterium, a fungus, or a virus. The vertebrate includes a bird and a mammal. The peptide has antipyretic, anti-inflammatory, anti-bacterial, antifungal, and antiviral properties and therefore can be administered at the onset of the ophthalmic condition before the insult causing the condition is determined as well as thereafter.

IC ICM A61K039-00
ICS A61K039-38
NCL 424184100
CC 1-5 (Pharmacology)
Section cross-reference(s): **63**
IT 4037-01-8 22006-64-0, α1-13-Corticotropin **67727-97-3**
296231-52-2 644963-12-2D, dimer 644963-13-3 644963-14-4
644963-15-5 644963-16-6 644963-17-7 644963-18-8 644963-19-9
644963-20-2 644963-21-3 644963-22-4 644963-23-5 644963-24-6
644963-25-7 644963-26-8 644963-27-9
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α-MSH peptides in treatment of ophthalmic conditions)
IT **67727-97-3**
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α-MSH peptides in treatment of ophthalmic conditions)
RN 67727-97-3 CAPLUS
CN L-Valine, L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:696525 CAPLUS
DOCUMENT NUMBER: 139:207828
TITLE: Peptides for the treatment of hyperpigmentation conditions
INVENTOR(S): Thody, Anthony J.; Wood, John M.; Schallreuter, Karin U.
PATENT ASSIGNEE(S): UK

SOURCE: U.S. Pat. Appl. Publ., 8 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003166570	A1	20030904	US 2001-777656	20010207

PRIORITY APPLN. INFO.: US 2001-777656 20010207
OTHER SOURCE(S): MARPAT 139:207828

AB The invention discloses peptides X-N(H)-A1-B2-C3-D4-Lys5-Lys6 -Arg7-C(O)-Y (A, B, C, D = amino acid residues; X = H, pharmaceutically acceptable amine blocking group, and, together with Y, a covalent bond connecting the carbonyl group of Arg7 to the amine group of A1; Y = OH, pharmaceutically acceptable carboxyl blocking group, and, together with X, a covalent bond connecting the carbonyl group of Arg7 to the amine group of A1). The peptides may be used topically to treat hyperpigmentation conditions, e.g. melanism and melasma.

IC ICM A61K038-08
ICS C07K007-06
NCL 514016000; 530329000
CC 1-12 (Pharmacology)
Section cross-reference(s): **63**
IT 7266-47-9, α1-17-Corticotropin **67727-97-3**
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(peptides for treatment of hyperpigmentation conditions)
IT **67727-97-3**
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(peptides for treatment of hyperpigmentation conditions)
RN 67727-97-3 CAPLUS
CN L-Valine, L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:455013 CAPLUS
DOCUMENT NUMBER: 139:30811
TITLE: Compound and method for the treatment of **sinusitis** with α-MSH peptides having KPV motif at C-terminus
INVENTOR(S): Catania, Anna P.; Lipton, James M.
PATENT ASSIGNEE(S): Italy
SOURCE: U.S. Pat. Appl. Publ., 37 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003109453	A1	20030612	US 2001-15055	20011210

PRIORITY APPLN. INFO.: US 2001-15055 20011210

AB The invention includes a composition and method of treatment of sinusitis. A preferred embodiment of the invention is a composition for treatment of sinusitis comprising a therapeutically effective amount of one or more peptides selected from the group of peptides with a C-terminal sequence consisting of KPV, HFRWGKPV, and SYSMEHFRWGKPV used in combination with a therapeutically effective amount of an antihistamine/decongestant, corticosteroid, fungicide and/or antibiotic. In yet another embodiment of the invention, one or one or more peptides selected from the group of peptides with a C-terminal sequence consisting of KPV, HFRWGKPV, and SYSMEHFRWGKPV, which may or may not be in combination with therapeutically effective amts. of antibiotics, corticosteroids and/or antihistamine/decongestants, are topically or systemically applied to treat sinusitis.

IC ICM A61K038-00
NCL 514014000
CC 1-7 (Pharmacology)
Section cross-reference(s): 2, **63**
ST **sinusitis** treatment KPV peptide; alphaMSH peptide treatment **sinusitis**
IT Peptides, biological studies
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C-terminal KPV motif-containing; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)
IT Protein motifs
(KPV; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)
IT Physiological saline solutions
(as pharmaceutical carrier; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)
IT Gelatins, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as pharmaceutical carrier; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)
IT Drug delivery systems
(carriers; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)
IT Antibiotics
Antihistamines
Decongestants
Fungicides
(in combination; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)
IT Glucocorticoids
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in combination; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)
IT Physiological saline solutions
(phosphate-buffered, as pharmaceutical carrier; α-MSH peptides

having KPV motif at C-terminus for treatment of **sinusitis**)

IT Conformation
(protein, peptide; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)

IT **Respiratory** tract, disease
(**sinusitis**; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)

IT Drug delivery systems
(tablets; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)

IT Spore germination
(α-MSH and peptides inhibition of, of Candida albicans; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)

IT Candida albicans
(α-MSH and peptides inhibition of; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)

IT Neutrophil
(α-MSH enhancement of Candida albicans killing by human; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)

IT Anti-inflammatory agents
(α-MSH peptide as; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)

IT Drug delivery systems
Human
(α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)

IT Interleukin 6
Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α-MSH reduction of production of; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)

IT 82219-24-7
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(Candida albicans response to; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)

IT 57899-96-4 137359-87-6 137359-89-8 137359-90-1
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiinflammatory effects of; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)

IT 9004-32-4, Carboxymethyl cellulose 9004-34-6, Cellulose, biological studies 9004-67-5, Methyl cellulose 9050-36-6, Maltodextrin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as pharmaceutical carrier; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)

IT 50-02-2, Dexamethasone 50-23-7, Hydrocortisone 53-03-2, Prednisone 53-06-5, Cortisone 59-42-7, Phenylephrine 69-53-4, Ampicillin 86-21-5, Pheniramine 86-22-6 90-82-4, Pseudoephedrine 113-92-8, Chlorpheniramine maleate 114-07-8, Erythromycin 124-94-7, Triamcinolone 147-52-4, Nafcillin 378-44-9, Betamethasone 1247-42-3, Methylprednisone 1406-05-9, Penicillin 14838-15-4, Phenylpropanolamine 22916-47-8, Miconazole 26787-78-0, Amoxicillin 27220-47-9, Econazole 51333-22-3, Budesonide 64544-07-6, Cefuroxime axetil 65277-42-1, Ketoconazole 74469-00-4 79794-75-5, Loratidine 81103-11-9, Clarithromycin 83905-01-5, Azithromycin 84625-61-6, Itraconazole 86386-73-4, Fluconazole 87239-81-4, Cefpodoxime proxetil

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in combination; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)

IT **67727-97-3**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptide containing C-terminal; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)

IT 37353-59-6, Hydroxymethyl cellulose
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(with glycerin, as pharmaceutical carrier; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)

IT 56-81-5, Glycerin, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(with hydroxymethyl cellulose, as pharmaceutical carrier; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)

IT 581-05-5, α-Melanotropin (swine) 22006-64-0, α1-13-Corticotropin 37213-49-3, α-MSH 102967-74-8 296231-52-2 457605-12-8
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)

IT 137359-88-7
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)

IT 63-42-3, Lactose 134-03-2, Sodium ascorbate 557-04-0, Magnesium stearate 7718-59-4 9003-39-8, Polyvinylpyrrolidone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)

IT 60-92-4, CAMP
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α-MSH peptides in Candida albicans accumulation of; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)

IT 14797-65-0, Nitrite ion, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α-MSH reduction of production of; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)

IT **67727-97-3**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptide containing C-terminal; α-MSH peptides having KPV motif at C-terminus for treatment of **sinusitis**)

RN 67727-97-3 CAPLUS
CN L-Valine, L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:155980 CAPLUS
DOCUMENT NUMBER: 138:163511
TITLE: Use of tripeptide Lys-Pro-Val (KPV) in the treatment of melanomas
INVENTOR(S): Mahe, Yann
PATENT ASSIGNEE(S): L'Oreal, Fr.
SOURCE: Fr. Demande, 28 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2826581	A1	20030103	FR 2001-8680	20010629

PRIORITY APPLN. INFO.: FR 2001-8680 20010629

AB The invention discloses the use of at least one peptide containing at least the sequence KPV, or at least one functional equivalent of such a peptide, in a dermatol. and/or pharmaceutical composition for the reduction of expression of macrophage migration inhibitory factor (MIF), usually overexpressed in melanomas.

IC ICM A61K038-02
ICS A61K038-06; A61K007-48; A61P035-00; A61P017-06
CC 1-6 (Pharmacology)
Section cross-reference(s): 63
IT **67727-97-3**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides containing tripeptide KPV sequence for treatment of melanoma and other conditions)
IT **67727-97-3D**, isomers **125905-17-1**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides containing tripeptide KPV sequence for treatment of melanoma and other conditions, and use with other agents)
IT **272450-28-9**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides containing tripeptide KPV sequence for treatment of melanoma and other conditions, and use with other agents)
IT **67727-97-3**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides containing tripeptide KPV sequence for treatment of melanoma and

other conditions)
RN 67727-97-3 CAPLUS
CN L-Valine, L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **67727-97-3D**, isomers **125905-17-1**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides containing tripeptide KPV sequence for treatment of melanoma and other conditions, and use with other agents)
RN 67727-97-3 CAPLUS
CN L-Valine, L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 125905-17-1 CAPLUS
CN L-Valine, L-lysyl-D-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **272450-28-9**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides containing tripeptide KPV sequence for treatment of melanoma and other conditions, and use with other agents)
RN 272450-28-9 CAPLUS

CN D-Valine, D-lysyl-D-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:778521 CAPLUS
DOCUMENT NUMBER: 137:284375
TITLE: A peptide compound for treatment of fungal pathologies in oral cavity
INVENTOR(S): Lipton, James M.
PATENT ASSIGNEE(S): Zengen, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 11 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002146374	A1	20021010	US 2001-774282	20010129
WO 2002064046	A2	20020822	WO 2002-US3039	20020122
WO 2002064046	A3	20030515		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-774282 A 20010129

AB The broadest aspect of the invention is a composition and method for treatment of fungal pathologies of the oral cavity, e.g, candidiasis, or fungal growth on the surface of dentures. A preferred composition comprises a pharmacol. effective amount of a peptide selected from the group of peptides with a C-terminal sequence consisting of KPV, HFRWGKPV, and SYSMEHFRWGKPV in combination with a therapeutically effective amount of a fungicide selected from the group consisting of: itraconazole, econazole, ketoconazole, miconazole and fluconazole or gram pos. and/or gram neg. antibiotics, such as aminoglycosides, amoxicillin, ampicillin, azithromycin, erythromycin, nafcillin, penicillin, quinupristin, dalfopristin and vancomycin.

IC ICM A61K007-28
ICS A61K038-16; A61K031-496; A61K031-43
NCL 424050000

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 62
IT 22006-64-0, α1-13-Corticotropin **67727-97-3** 466682-81-5
466682-82-6
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(peptide compds. for treatment of fungal pathol. in oral cavity and fungal growth on surface of dentures)
IT **67727-97-3**
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(peptide compds. for treatment of fungal pathol. in oral cavity and fungal growth on surface of dentures)
RN 67727-97-3 CAPLUS
CN L-Valine, L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:695710 CAPLUS
DOCUMENT NUMBER: 137:222061
TITLE: A sunburn treatment and sunburn prevention method
INVENTOR(S): Lipton, James M.
PATENT ASSIGNEE(S): Zengen, Inc., USA
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069884	A2	20020912	WO 2001-US51090	20011029

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-704327 A 20001101
AB The present invention is directed to a treatment for sunburn and a method for preventing sunburn. One aspect of this invention involves a sunburn treatment comprising one or more polypeptides with an amino acid sequence including KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ.

ID. NO. 3), or SYSMEHFRWGKPV (SEQ. ID. NO. 4) for the treatment of the cutaneous inflammation caused by exposure to UV radiation. The polypeptides are at a level to effectively treat the cutaneous inflammation and are carried by a carrier. The one or more polypeptides can also be a dimer formed from any of the amino acid sequences above. In one preferred embodiment of the invention, the one or more polypeptides are used to prevent sunburn. In another preferred embodiment, the one or more polypeptides are dissolved in a carrier. In another preferred embodiment, the carrier includes aloe vera and lidocaine hydrochloride. In another preferred embodiment of the invention, the one or more polypeptides are dissolved in a liquid that is associated with an absorbent material for application to sunburned skin.

IC ICM A61K
CC **63-6** (Pharmaceuticals)
Section cross-reference(s): 62
IT 4037-01-8 22006-64-0, α1-13-Corticotropin **67727-97-3**
296231-52-2 457605-12-8
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sunburn treatment and sunburn prevention method)
IT **67727-97-3**
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sunburn treatment and sunburn prevention method)
RN 67727-97-3 CAPLUS
CN L-Valine, L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:688107 CAPLUS
DOCUMENT NUMBER: 133:261547
TITLE: α-melanocyte-stimulating hormone (α-MSH) and peptide derivatives for treatment of urogenital conditions
INVENTOR(S): Lipton, James; Catania, Anna
PATENT ASSIGNEE(S): Zengen Inc., USA
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000056353	A2	20000928	WO 2000-US7846	20000323
WO 2000056353	A3	20001228		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1165120	A2	20020102	EP 2000-916651	20000323
JP 2002542158	T2	20021210	JP 2000-606257	20000323
US 2004006024	A1	20040108	US 2003-420578	20030421
US 2003176353	A1	20030918	US 2003-426647	20030429

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.:	US 1999-126233P	P 19990324
	US 2000-535066	A3 20000323
	WO 2000-US7846	W 20000323

AB The invention is directed to a system for treating urogenital conditions. One aspect of the invention involves a treatment system comprising one or more peptides with an amino acid sequence including KPV, MEHFRWG, HFRWGKPV, and/or SYSMEHFRWGKPV for treatment of urogenital conditions. The peptides can also be dimers formed from the above amino acid sequences. Urogenital conditions can include infections, inflammation, or both. In one preferred embodiment of the invention, the urogenital condition includes infection and/or inflammation of the vagina, vulva, urinary tract, penis, and/or rectum. In another preferred embodiment, the one or more peptides are dissolved in a carrier. In another preferred embodiment, the one or more polypeptides are associated with a tampon for preventing toxic shock syndrome. In another preferred embodiment, the one or more polypeptides are associated with a contraceptive for prevention of sexually transmitted diseases or infections. In another preferred embodiment, the one or more polypeptides are associated with a suppository for insertion into the vagina or rectum.

IC ICM A61K038-34
ICS A61K038-06; A61K038-08; A61P013-00; A61P015-00

CC 1-12 (Pharmacology)
Section cross-reference(s): 2, **63**

IT 581-05-5, α-Melanotropin (swine) 581-05-5D, α-Melanotropin (swine), peptide derivs. 4037-01-8D, dimers and D-amino acid derivs. 4037-01-8D, dimers and D-amino acid derivs. 10466-28-1 22006-64-0, α1-13-Corticotropin 22006-64-0D, α1-13-Corticotropin, dimers and D-amino acid derivs. 53697-27-1 57899-80-6 57899-96-4 65213-40-3 **67727-97-3 67727-97-3D**, dimers and D-amino acid derivs. 82219-24-7 87375-88-0 102967-74-8 110025-22-4 296231-52-2 296231-52-2D, dimers and D-amino acid derivs. 296231-56-6 296233-30-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α-MSH and peptide derivs. for treatment of urogenital conditions)

IT **67727-97-3 67727-97-3D**, dimers and D-amino acid derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α-MSH and peptide derivs. for treatment of urogenital conditions)

RN 67727-97-3 CAPLUS
CN L-Valine, L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 67727-97-3 CAPLUS
CN L-Valine, L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:180954 CAPLUS
DOCUMENT NUMBER: 126:176877
TITLE: α-Melanocyte stimulating hormone derivatives for the stimulation of hair growth or prevention of hair loss
INVENTOR(S): Mahe, Yann
PATENT ASSIGNEE(S): Oreal S. A., Fr.
SOURCE: Fr. Demande, 16 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2733421	A1	19961031	FR 1995-5158	19950428
FR 2733421	B1	19970606		
EP 759292	A1	19970226	EP 1996-400653	19960327
EP 759292	B1	19970326		
R: DE, ES, FR, GB, IT				
ES 2102921	T3	19970801	ES 1996-400653	19960327
JP 08301729	A2	19961119	JP 1996-108203	19960426
JP 2880125	B2	19990405		
US 5739111	A	19980414	US 1996-638774	19960429
US 6001812	A	19991214	US 1998-12233	19980123

PRIORITY APPLN. INFO.: FR 1995-5158 A 19950428
US 1996-638774 A1 19960429

AB α-MSH derivs., such as peptides containing Lys-Pro-Val, are useful for the stimulation of hair growth or prevention of hair loss. A hair lotion contained acetyl-Lys-Pro-Val-NH2 12.5x10-6, 2,4-diaminopyrimidine-3-oxide 0.75, 95° ethanol 30, perfume q.s., colors q.s., and water q.s. 100 g.

IC ICM A61K038-06
ICS A61K007-06

CC **63-3** (Pharmaceuticals)

IT 37213-49-3, α-Melanocyte stimulating hormone 57899-96-4, Acetyl-Lys-Pro-Val-NH2 **67727-97-3**, Lys-Pro-Val
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(α-MSH derivs. for stimulation of hair growth or prevention of hair loss)

IT **67727-97-3**, Lys-Pro-Val
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(α-MSH derivs. for stimulation of hair growth or prevention of hair loss)

RN 67727-97-3 CAPLUS

CN L-Valine, L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>

=>